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Role of Neutrophils in Osteoarthritis and Rheumatoid Arthritis 
Dong Zhan  
Objectives: The synovitis observed in knee osteoarthritis (OA) differs from that typically 
found in rheumatoid arthritis (RA). Fibroblast-like synoviocytes (FLS) may play a function 
in the development of synovitis by the production of inflammatory cytokines and 
chemokines or inflammatory mediators in synovial fluid. Neutrophil-derived microvesicles 
(NDMV) possess the capability of cartilage protection and anti-inflammatory effects. Thus, 
we investigated the expression of inflammatory cytokines produced by tumour necrosis 
factor alpha (TNFα)-stimulated FLS which were pre-treated with NDMV.  
Methods: FLS isolated from the synovium of patients with OA undergoing knee 
replacement were characterized by flow cytometry for fibroblast markers. Neutrophils 
were isolated from healthy volunteer blood and were characterized by cytospin and flow 
cytometry. NDMV, generated from TNFα-stimulated neutrophils, were characterized by 
electron microscopy, nanoparticle tracking analysis and flow cytometry. MicroRNAs of 
NDMV were sequenced by Illumina NextSeq500 and analysed by miRWalk 2.0 to predict 
target genes and possible signaling pathways. The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) assay was used to measure the viability of the FLS after 
NDMV treatment, while internalisation of fluorescently labelled NDMV was measured by 
flow cytometry and confocal microscopy. Levels of inflammatory cytokines in FLS 
cultured supernatants were quantified by the Bio-Plex suspension array system. 
Results: High purity (≥ 95%) of FLS in sub-culture at passage 4 were prepared from OA 
synovium. Isolated neutrophils (purity > 98%) were treated for 20min treatment with 
50ng/ml TNFα prior to preparation of NDMV. Isolated NDMV (diameter range from 200 
to 500nm) expressed more Annexin V and CD63 on their membrane surface than untreated 
control neutrophils. Incubation of FLS with NDMV at a ratio of 1:100 resulted in a time-
dependent uptake, with 35% of synoviocytes containing microvesicles over a 6-24h time-
period, with no significant change in cell viability. NDMV contained 159 different 
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microRNAs which were predicted to interact with 7,978 target genes. 74 and 26 target 
genes of NDMV-carried microRNAs were predicted to interact with phosphatidylinositol 
3-kinase (PI3K)/protein kinase B (AKT) and mitogen-activated protein kinase (MAPK) 
signaling pathways, respectively (p<0.0001). TNFα (10ng/ml) stimulated the expression 
of a number of cytokines and chemokines from synoviocytes and NDMV down-regulated 
this TNFα-induced expression of interleukin (IL)-5, IL-6, IL-8. Monocyte chemotactic and 
activating factor (MCP)-1, interferon (IFN)γ and macrophage inflammatory proteins 
(MIP)-1β (p<0.01). However, this down-regulation was selective, as NDMV had non-
significant effects on TNFα-stimulated expression of granulocyte colony stimulating factor 
(G-CSF), IL-17, IL-2 or IL-4.  
Conclusions: NDMV are internalised by FLS and can selectively inhibit TNFα-stimulated 
inflammatory cytokine/chemokine secretion. This process may occur via NDMV-carried 
microRNAs negatively regulating post-transcriptional control of PI3K-AKT and MAPK 
signaling pathways. NDMV therefore may perform an anti-inflammatory role in the 
regulation of FLS function in synovitis. More research is necessary to identify if NDMV 





There is only one form of heroism in the world: 
      to see the world as it is, and to love it. 
—Romain Rolland— 
 
OA and RA are the two most prevalent forms of arthritis. Synovitis is detectable in affected 
joints of both conditions. Until recently, medical doctors and clinical scientists have had to 
face a shortage and limitation of effective treatments and even newer therapies are not 
always effective. It is therefore necessary to explore the role of novel therapies to improve 
joint function and relieve symptoms. Extracellular vesicles (EV) are a useful form of 
communication between cells, while neutrophil-derived microvesicles (NDMV), generated 
from stimulated neutrophils are reported to inhibit inflammation in some recipient cells. 
NDMV can also regulate chondrocytes to protect cartilage. My supervisor from 
Chulalongkorn University is an expert in OA, and supervisors from University of Liverpool 
are specialists in RA and neutrophils. It is appropriate to combine two research fields of 
FLS, neutrophils and NDMV. This research may eventually lead to NDMV applications in 
clinical practice for the treatment of inflammatory diseases.  
          Chapter 1 contains a brief description of research questions in osteoarthritis (OA) 
and rheumatoid arthritis (RA) and neutrophil-derived microvesicles (NDMV). The 
objectives, experimental design and hypothesis of the research in this thesis are stated in 
this opening chapter. Chapter 2 provides an overview of the current research developments 
and outstanding issues in OA, RA and NDMV. Synovitis is a common feature of both OA 
and RA whereas NDMV have the ability to inhibit the inflammatory response of recipient 
cells.  In Chapter 3, experimental materials and methods are described to culture FLS, 
isolate NDMV, evaluate the characteristics of cells and NDMV, measure levels of 
cytokines and analyse microRNAs in neutrophils and NDMV. Bioinformatic methods were 
used to predict target genes of these microRNAs.  In Chapter 4, after data were statistically 
analysed, experimental results are presented and the results section is composed of 4 parts: 
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FLS culture and characterisation; neutrophil isolation and functional properties; NDMV 
isolation and properties; the effects of NDMV on FLS. Chapter 5 contains discussion of 
the major findings in this research and the limitations. In Chapter 6 we speculate that 
NDMV could modulate FLS to prevent an inflammatory response through microRNA. We 
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Chapter 1. INTRODUCTION 
1.1 Problem description  
Osteoarthritis (OA) is often wrongly considered to be a disease of “tear and wear” and a 
primary defect of cartilage in synovial joints, and low-grade and chronic inflammation is 
often present in the synovium of affected joints. Rheumatoid arthritis (RA) is an 
autoimmune disorder that affects multiple organs. Its main manifestation is high-grade 
inflammation in tissues, especially the synovium that can result in cartilage and bone 
erosion. Hence, although OA and RA are two entirely different types of arthritis, both are 
associated with cartilage damage and synovial inflammation (synovitis) to various degrees. 
Synovitis in RA is extensive, involving the whole synovium in affected joints, but in OA 
synovitis appears in discrete locations of synovium named after “inflamed area” with 
hyperplasia and hypervascularity (Deligne et al., 2015).  
         Macrophages and T cells are two predominant immune cells that migrate from the 
blood stream to the synovium in OA and RA. Neutrophils are, however, the major 
infiltrating cell (about 50.6%) in the synovial fluid (SF) of RA joints, in comparison to OA, 
where neutrophils are typically less abundant (11.3%) (Rolle et al., 2019). An earlier study 
reported that the absolute number of neutrophils in OA SF (5ml) was 70.50%, which is 
lower than that in RA SF 79.17% (Abd-El-Hafez et al., 2014). Beside cartilage loss and 
low-grade synovitis, OA is also characterized by osteophytes, sclerosis and subchondral 
bone cysts. Another frequently observed histological feature in RA is a synovial pannus, 
induced by long-term synovitis and Figure 1 illustrates the differences in synovial joints 
between OA and RA compared to normal, healthy control joints. The occurrence of OA 
increases with age and is two-fold greater in those over 60 years, with a predominance in 
females. While the prevalence of RA is also higher in females, the age of onset is typically 
lower than in OA (Woolf and Pfleger, 2003). Both OA and RA result in pain, dysfunction 
and potentially failure of joints, diminishing the quality of life. They also bring heavy social 
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and economic burden both for governments and families. It is necessary to develop novel, 
effective and safe therapies for the improvement of human health, otherwise these diseases 
will continue to negatively influence millions of families across the world.   
 
 
Figure 1. Schematic diagram comparing synovium, subchondral bone and synovial fluid 
between normal, OA and RA knee joints. Hyaline cartilage covers the ends of opposing 
articulated bones. Articular capsule is composed of fibrous membrane/capsule (outer layer) 
and synovial membrane/synovium (inner layer). Synovial fluid (SF) filled in potential joint 
cavity. OA knee is characterized with cartilage degradation and loss and cartilage 
fragments could be found in SF. Osteophytes also appears around the cartilage. 
Subchondral bone presents eburnation and cysts. In RA knee, pathological manifestations 
are mainly on synovium: overgrowth (projection and pannus) and edema results from high-
grade synovitis. Osteopenia could appear in subchondral bone of RA. T cells and 
macrophages are two major cellular types found in the synovium and SF of arthritis. 
Neutrophils are recruited to either in the synovial cavity or membrane to spread 




         NDMV are one type of extracellular vesicles (EV) that are generated by neutrophils 
exposed to various stimulants, such as N-formyl-methionyl-leucyl-phenylalanine (fMLP), 
interleukin (IL)-6 and tumor necrosis factor (TNF) alpha. Although neutrophils are the 
predominant type of leukocytes (60-70%) in the circulation of healthy individuals, platelet-
derived, rather the neutrophil-derived MV form the majority of total EV in circulating 
blood (Daniel et al., 2006). In RA the level of platelet-derived MV’s positively correlates 
with disease activity, as determined by the disease activity score-28 (DAS28)  (Knijff-
Dutmer et al., 2002). NDMV have the potential to increase inflammation in endothelial 
cells in various vascular  tissues such as brain microvessels, coronary arteries and umbilical 
veins (Ajikumar et al., 2019). Other pro-inflammatory mediators, such as IL-1β, IL-6, IL8, 
reactive oxygen species (ROS) etc., are expressed by endothelial cells exposed to NDMV 
(Mesri and Altieri, 1999, Mesri and Altieri, 1998). However, whether NDMV’s perform 
an anti- or pro- inflammatory role depends on the recipient cell. For example, NDMV’s 
exert a pro-inflammatory effect on endothelial cells, but an anti-inflammatory effect on 
myeloid cells (L Johnson et al., 2014).  
         In inflammation, whether induced by external factors (such as infection) or internal 
stimuli (such as in RA) stimuli, NDMV may be rapidly generated by infiltrating neutrophils 
at inflammatory sites. NDMV’s down-regulate pro-inflammatory cytokines (IL-8, IL-10 
and TNFα) expression from monocyte-derived macrophages and, conversely, elevation of 
the anti-inflammatory cytokine, Transforming Growth Factor beta (TGFβ)  (Headland and 
Norling, 2015). The anti-inflammatory function of NDMV not only relies on surface 
proteins on NDMV membranes, but also on the content of NDMV. NDMV can be loaded 
with high levels of Annexin A1 and A5, myeloperoxidase, phosphatidylserine, etc. (Dalli 
et al., 2013). Microvesicles (MV) from the plasma of healthy volunteers contained 
substantial microRNAs and there were an identical 71 different microRNAs that were also 
found in monocytes (Hunter et al., 2008). It was reported that the proportion of CD66b+ 
(a neutrophil CD marker) on the MV was less than 5%. However, the CD66b+ MV 
percentage was highest among other cells derived MV (CD14+ or CD3+) from SF of RA. 
It may therefore be speculated that NDMV’s possess microRNAs that could exert an 
influence on synovitis. In fact, exosomes (Exo) selectively assemble specific microRNAs, 
such as microRNA-320, 451 and 150, and MV selectively are loaded with pre-matured 
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microRNAs (Chen et al., 2009, Guduric-Fuchs et al., 2012). Recently, a study from Gomez 
et al. suggested that NDMV could up-regulate inflammatory cytokine expression in 
endothelial cells of the coronary artery via their cargo of miR-155 (Gomez et al., 2020). 
         Fibroblast-like synoviocytes (FLS) are the main cells types that forms the intimal 
layer of the synovium. They not only produce the lubricating synovial fluid essential for 
normal joint function, but also inflammatory- or metabolic-mediators to modulate the local 
joint environment. FLS treated by IL-1, IL-6 or TNFα etc. were commonly used to develop 
the cellular model of synovitis in in vitro studies. T cell-derived and monocyte-derived 
microvesicles (TDMV and MDMC) could induce FLS to up-regulate cyclooxygenase-2 
(COX-2) gene expression and prostaglandin E2 (PGE2) levels, thereby promoting an 
inflammatory response, together with increased pro-angiogenetic chemokines expression, 
and elevated matrix metalloproteinases (MMP)-1, 3, 9 and 13 (Reich et al., 2011, Jungel 
et al., 2007, Distler et al., 2005b). Headland et al. proposed that NDMV could mediate a 
beneficial effect on chondrocytes (Headland et al., 2015), while Rhys et al. showed that 
the secretion of inflammatory cytokines was suppressed in FLS that had been co-cultured 
with macrophages treated by NDMV (Rhys et al., 2018). Eken et al. reported that NDMV 
could inhibit macrophage function through various signaling pathways, for example, via 
phosphatidylinositol 3-kinase-protein kinase B (PI3K-AKT), the MER proto-oncogene 
tyrosine kinase (MerTK) pathway and the Toll-like receptor (TLR)-2 pathway (Eken et al., 
2013, Eken et al., 2010).  
 
1.2 Aims  
In the view of previous findings, the aim of this thesis was to investigate the direct impact 
of NDMV on the function of FLS and to determine how this interaction could affect 
inflammation. Highly-purified FLS, obtained by primary synoviocyte culture, were used 
to generate a cellular model of synovitis induced in vitro by TNFα exposure. Secondly, 
highly-pure populations of neutrophils were stimulated to generate NDMV and their 
properties and characteristics, including their microRNAs were investigated. The level of 
inflammatory cytokine s from FLS with or without treatment with NDMV were measured. 
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The probable mechanism of these effects of NDMV-mediate changes in FLS function were 
analyzed via NDMV-containing microRNAs and their predicted effects of the regulation 
of target genes by bioinformatic approaches. 
 
1.3 Flowchart of experimental design  
The experimental plan is divided into four parts: neutrophil isolation and their functional 
assays; FLS culture and characteristics; NDMV isolation, purification and properties assay, 
determination of the effect of NDMV to FLS. High purity of neutrophils and FLS are 




Figure 2. Flowchart of experiment design. This research work consists neutrophils, FLS 





• FLS cultured in vitro maintain their capabilities of proliferation and inflammatory 
response. 
• Neutrophils remain functional and non-apoptotic after treatment by high-dose and short 
-term exposure to TNFα prior to generation of NDMV. 
• NDMV are loaded abundant microRNAs that are different to those expressed in intact 
neutrophils. 
•  FLS internalize NDMV to suppress inflammatory cytokine secretion via packaged 






Chapter 2. BACKGROUND AND LITERATURE REVIEW 
Arthritic conditions are characterized by joint pain and loss of function and can be 
categorized into more than 100 different types. Redness, swelling, heat, pain and 
dysfunction are five major clinical components of arthritis. Osteoarthritis (OA) and 
Rheumatoid Arthritis (RA) are the two most prevalent types of arthritis and affect both 
males and females. Although OA and RA have some similarities in symptoms and signs, 
their etiologies, diagnosis and therapies are very different. The aetiology of OA has not 
been fully elucidated. It has traditionally been thought to be caused by mechanical wear 
and tear on overloaded or overused joints, resulting in cartilage damage. In contrast, RA is 
an autoimmune disorder, where the immune system mediates damage to joints and other 
organs in the absence of infection. Despite extensive ongoing research worldwide, the full 
etiologies of these disease, and hence the most effective treatments for these important 
conditions remain only partly known. 
 
2.1 Osteoarthritis (OA)  
OA was first described over 230 years ago. In 1782, William Heberden (1710–1801), a 
physician of the United Kingdom (UK), recorded symptoms and described the OA 
“Digitorum Nodi” which were later renamed  Heberden’s nodes (Dequeker and Luyten, 
2008). In 1859, the term RA was proposed by Alfred Baring Garrod who considered OA 
and RA to be two different diseases. In 1987, the American College of Rheumatology 
(ACR) defined OA as “a heterogeneous group of conditions that lead to joint symptoms 
and signs, which are associated with defective integrity of articular cartilage, in addition to 
related changes in the underlying bone at the joint margins” (Arnett et al., 1988).  
         OA is recognized as a joint disease caused by articular cartilage loss in focal areas in 
synovial joints. It is associated with articular bone and capsule pathological changes: 
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osteophytes, subchondral bone sclerosis, capsule thickening, etc. Both weight-bearing 
joints (coxafemoral, tibiofemoral, talocrural, and intervertebral joints) and non-weight-
bearing joints (interphalangeal joints of fingers or toes, etc.) can be affected. Histologically, 
cartilage is a type of connective tissue without vessels and nerve supply, therefore, the 
shortage of oxygen and nutrients attenuates the viability of chondrocytes and their potential 
for tissue repair. The clinical manifestations of OA include pain or tenderness, crepitus and 
limitation of movement in affected joints. 
2.1.1 Risk factors of OA 
Although the pathogenesis of OA is still unclear, its risk factors are known to be 
multifactorial. It is distinguished from other types of arthritis by massive loss, and failure 
of cartilage restoration. Multiple factors can contribute to accelerated cartilage damage and 
impaired cartilage repair. Systematic factors include ageing, gender, genetics, nutrients, 
bone density, smoking, etc. and local factors include occupation, biomechanical stress, 
trauma, muscle strength, inflammation, infection, manual labor, etc. (Garstang and Stitik, 
2006). Ageing is a major factor in OA (Valdes and Stocks, 2018, Sacitharan, 2019). The 
disease progresses gradually and methods to reverse this joint destruction have yet to be 
discovered. Current treatment therefore focuses on symptomatic care with physiotherapy 
or painkillers leading to joint replacement surgery where required. 
2.1.2 Categories of OA 
OA is categorized into two types: primary and secondary, according to the classification of 
OA causes (Doherty et al., 1983). Primary OA is also called idiopathic OA, as no definite 
cause has yet been identified. It could be caused by natural ageing of the musculoskeletal 
system and appears to have families- and genetic-predispositions. Primary OA can be 
subdivided into common nodal OA occurring in most synovial joints and the less frequent 
erosive OA in distal interphalangeal joints. Multiple factors appear to underlie secondary 
OA, including joint trauma and/or infection, congenital deformity, metabolic disorders, 
systemic diseases, vocations, etc. In comparison to primary OA, secondary OA is linked 
more closely with known underlying causes. 
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2.1.3 Epidemiology of OA 
Osteoarthritis is the third most frequent diagnosis made by general practitioners among 
older adults. It not only causes pain, but it also reduces the quality of life. As OA progresses, 
patients may have to adapt to the disability resulting from reduced joint function. 
According to the World Health Organization (WHO), approximately 9.6% of male adults 
over 60 years old report OA-related symptoms, with a 2-fold higher prevalence in females 
(Woolf and Pfleger, 2003). The prevalence of OA is high across the world. In the United 
States (US), the National Institutes of Health (NIH) reported that there were about 
40,000,000 individuals with OA in in 2008, and this was predicted to rise by 20,000,000 
some twenty years later (Lawrence et al., 2008). OA symptoms in the knee are reported by 
15% of Americans over the age of 60 years (Jordan et al., 2007). Versus Arthritis, the 
largest charity for arthritis research and care in the UK, reported that one fifth adults over 
the age of 45 suffered from knee OA in England. They estimate the prevalence rate of knee 
OA is therefore 15% to 21% of the population in England (Versus Arthritis, 2013).  
         In general, the prevalence of knee OA was reported as 7.9% in Asia, with some 
variation between countries. The incidence of knee OA was 7.5% in mainland of China, 
while in Thailand, researchers investigated rural regions by questionnaire and reported that 
the  prevalence of OA was 11.3% (Chaiamnuay et al., 1998). Furthermore, there is a 
contrast between rural and urban regions: 13.7% of symptomatic knee OA in rural areas, 
compared to 6.0% in urban areas (Fransen et al., 2011). The difference in prevalence of 
OA with gender and age are well known. For example, the incidence of OA in females 
from 65 to 74 years constitutes the highest incidence with 1.4% diagnosed per each year 
while for men, over 75 years, it the incidence of OA is about 0.9% per year (Woolf and 
Pfleger, 2003). This positive correlation between age and incidence of OA is similar 
worldwide (Woolf and Pfleger, 2003, Sacitharan, 2019). In Queensland, Australia, 
researchers found that the incidence of primary OA was 88% in female OA patients. In 
contrast, the incidence of secondary OA was greater in male patients at roughly 82% 
(Cooper et al., 2013).  
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2.1.4 Diagnosis of OA 
According to the diagnostic criteria from the American College of Rheumatology in 1986, 
knee OA is diagnosed by clinical manifestations, radiographic features and laboratory tests 
(Altman et al., 1986). Therefore, a diagnosis of knee OA is made from a combination of 
clinical, radiographic and laboratory examinations. Panel 1-3 shows the diagnostic process 
for this diagnosis.  
 
Panel 1. Clinical diagnosis criteria of knee OA based on ACR. 
If 1 plus at least 3 items from 2-7 are present: 
1. Knee pain for most days of previous month 
2. Crepitus on active joint motion 
3. Morning stiffness lasting 30 min or less 
4. Age 50 years or older 
5. Bony enlargement of the knee on examination 
6. Bony tenderness 
7. No palpable warmth 
 
Panel 2. Clinical and radiographic diagnosis criteria of knee OA based on ACR. 
If 1 and 2 plus at least 1 item from 3-6 are present: 
1. Knee pain for most days of previous month 
2. Osteophytes at joint margins on radiographs 
3. Age 50 years or older 
4. Crepitus on active joint motion 
5. Morning stiffness lasting 30 min or less 
6. No palpable warmth 
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         The severity of knee OA is evaluated by the Kellgren-Lawrence (KL) Grading 
System according to X-ray images conducted by radiologists. Grade 1 to 4 is used to 
quantify each knee of each OA patient (Panel 4). However, the ACR criteria are not reliable 
to confirm non-serious OA at an early stage but it has advantages for the identification of 
advanced OA stages with later findings (Peat et al., 2006).  
 
Panel 3. Clinical and laboratory diagnosis criteria of knee OA based on ACR. 
If 1 plus at least 5 items from 2- are present: 
1. Knee pain for most days of previous month 
2. Crepitus on active joint motion 
3. Morning stiffness lasting 30 min or less 
4. Age 50 years or older 
5. Bony enlargement of the knee on examination 
6. Bony tenderness 
7. No palpable warmth 
8. Erythrocyte sedimentation rate (Westergren) < 40mm/h 
9. Rheumatoid factor < 1:40 










Panel 4. The Kellgren-Lawrence Grading System on X-ray examination. 
Grade 1: Unlikely narrowing of the joint space, possible osteophytes. 
Grade 2: Small osteophytes, possible narrowing of the joint. 
Grade 3: Multiple, moderately sized osteophytes, definite joint space narrowing, some 
sclerotic areas, possible deformation of bone ends. 
Grade 4: Multiple large osteophytes, severe joint space narrowing, marked sclerosis 
and definite bony end deformity. 
Note: Joint space narrowing-bone is visible on X-ray but the articular cartilage that 
covers it is not; a normal joint therefore appears to have a space between the bones; any 
decrease in space implies a reduction in cartilage cover. Osteophytes is small bony 
projections that form around joint margins, that are responsible for limiting the range of 
motion and can cause of pain.  Sclerosis, defined as pathological “hardening” and is a 
sign of osteoarthritis, seen as increased white areas in the bone at the joint margins. 
 
2.1.5 Treatment of OA 
OA is a condition still lacking effective treatments that can target the underlying problem. 
Pain and stiffness are prominent symptoms OA and relieving these symptoms to maximise 
quality of life, underpins all therapeutic strategies. Pharmacological treatments focus on 
analgesia  and acetaminophen (paracetamol) is recommended to control moderate pain 
(Zhang et al., 2007) while non-steroidal anti-inflammatory drugs (NSAID) are also often 
used, but can produce side effect such as gastric ulcer, hepatotoxicity, bleeding (Osani et 
al., 2019). For surgical treatment, intra-articular corticosteroid or hyaluronic acid injection 
may reduce knee pain and lubricate joint movement. Synovial excision may decrease 
synovial inflammation and joint pain, when coupled with intra-articular lavage. Tibial 
wedge osteotomy is a potential option for some patients who have a relatively small varus 
angulation (less than 10 degrees) and stable ligamentous support. Joint 
replacement/arthroplasty is an effective treatment for OA patients with severe 
manifestations or disability, particularly in the knee. Physical therapy can help to improve 
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muscle strength, stabilize the joint and hence decrease pain. Other conservative therapies 
include acupuncture, electrotherapy and ultra-sonic therapy. Intraarticular mesenchymal 
stem cell (MSC) injection has the potential has the potential to help repair cartilage and 
reduce pain (Mancuso et al., 2019). but as yet there is insufficient data to support its use. 
Knee joint distraction is new therapy that has the potential to decrease cartilage physical 
stress. One study reports joint function was improved and pain was relieved effectively by 
this technique (Takahashi et al., 2019). 
2.1.6 Synovitis of OA 
Cartilage loss is a well-known feature of OA. However, inflammation is also becoming 
recognized to be an important factor. Synovial inflammation/synovitis in OA has been 
shown by histological, radiographic and arthroscopic examinations (Guermazi, 2019, Rein 
et al., 2019). Such synovitis is related to the clinical manifestation, joint structure changes 
and likely contributes to the pathophysiological process. A previous study has reported that 
whilst synovitis is often present in patients with early OA, it was not apparent in advanced 
disease (Haywood et al., 2003). Different grades of synovitis, from mild to moderate, were 
observed in OA histological samples on microscopy. Magnetic resonance imaging (MRI) 
and ultrasound Doppler have confirmed synovitis in early stage of OA, consistent with 
inflammatory findings on histology (Pearle et al., 2007, Guermazi, 2019, Sarmanova et al., 
2016) and radiographic severity of X-ray. In a cross-sectional study, investigators found 
that the Odds Ratio (OR) of synovitis score on contrast-enhanced MRI increased with 
Kellgren & Lawrence (KL) grades in knee OA patients (Guermazi et al., 2014). In the 
rabbit OA model, researchers found that the severity of OA caused by meniscectomy could 
be worsen with synovitis induced by calcium pyrophosphate dihydrate (Fam et al., 1995). 
 
2.2 Rheumatoid Arthritis (RA) 
RA is common type of arthritis, caused by an autoimmune mediated chronic inflammation 
of joints. It is also a systematic disorder that can cause problems in extra articular areas 
including the lungs and cardiovascular system. RA typically affects the small synovial 
joints in the hands or toes, such as the metacarpophalangeal (MCP) and proximal 
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interphalangeal (PIP) joints, but other synovial joints such as in the in the upper and lower 
limbs are also often affected. 
         The pathogenesis of RA appears to involve multiple factors that include abnormal 
immunity, genetic background and smoking. Before syndromes and signs commence, the 
immune system of RA patients may show some differences from those of healthy control 
individuals. Anti-citrullinated protein antibodies (ACPA) and rheumatoid factor (RF) can 
be detected more than 10 years prior to the onset of symptoms (Wegner et al., 2010). The 
epitope of ACPA recognizes exo- or (modified) endogenous antigens to form circulating 
soluble antigen-antibody immune complexes, which may combine with RF to promote 
their activity (Arend and Firestein, 2012). These antigen-antibody complexes can stimulate 
innate immunity in the synovium and cause inflammation. Synovitis increases vascular 
permeability to recruit more inflammatory cells and produce more inflammatory cytokines 
in the synovial fluid (SF). The greatest genetic susceptibility to RA is located within the 
class II major histocompatibility complex (MHC) (Okada et al., 2014).  
2.2.1 Risk factors of RA 
What causes RA is also still unclear, but multiple factors are likely to be involved.  A case-
control study reported that up to 40% of descendants could inherit RA related genes from 
their parents (Frisell et al., 2013). Researchers also found that the risk of inheriting RA 
from a parent who is RF/ACPA positive rises to 50%”. Patients with RF/ACPA+ RA tend 
to present at an earlier age than those without. Multiple gene loci are confirmed to be risk 
factors: these include human leukocyte antigen (HLA)-DRB1, STAT4, TRAF1, FOXO3, 
etc.  (Gregersen et al., 1987, Kurreeman et al., 2007, Mohamed et al., 2012, Lee et al., 
2013). Age and gender are other risk factors. The incidence of RA is increased two fold in 
females compared to males (Myasoedova et al., 2010). Environmental risk factors, such as 
smoking induced citrullination of protein, also play role in RA occurrence (Tobón et al., 
2010).  
2.2.2 Categories of RA  
According to the classification criteria established by the American College of 
Rheumatology and European League Against Rheumatism (EULAR), RA can be 
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categorized into 3 types/phase depending upon disease progress (Aletaha et al., 2010a). 
These are: Phase 1/Early RA: clinical manifestation and laboratory examination that 
supports RA diagnosis and the presence of early synovitis; Phase 2/Developing RA: 
considering clinical and laboratory results to deduce RA and the possibility of developing 
possibility-constant inflammatory or erosive arthritis; Phase 3/Definite RA: integrating 
information of Phase 1 and 2 to improve grading system and confirm RA. 
2.2.3 Epidemiology of RA 
In a Global Burden of Disease 2010 study, the incidence of RA was estimated to be around 
0.24% worldwide (Cross et al., 2014), while in an earlier study, the incidence of RA was 
considered to be higher, between 0.4-1.3% (Felson, 1990). The reasons for this apparent 
decline in RA prevalence over time are unclear.  In developed countries, the RA prevalence 
rate ranges from 0.5% to 1% in adults (Gabriel and Michaud, 2009). In Woolf and Pfleger’s 
study, it appears to be the prevalence of RA in developing countries that was higher than 
that of developed countries in the populations <60 years old. However, individuals > 60-
years of age from developed countries had higher RA prevalence than developing countries 
(Woolf and Pfleger, 2003). In the UK, the prevalence of RA is 1.16% in UK females and 
0.44% in UK males, while in Asian countries, RA prevalence is 0.2-0.93% in mainland 
China, and 0.12% in Thailand (Chaiamnuay et al., 1998, Zeng et al., 2008).  
2.2.4 Diagnosis of RA 
RA diagnosis is currently based on the 2010 ACR/EULAR classification criteria. The 
scoring system includes clinical features, serology, duration of symptoms and laboratory 
















Joint distribution (0–5 points) Points points 
Joint involvement: Any swollen or tender joint (excluding DIP of hand and 
feet, 1st MTP, 1st CMC) or additional evidence from MRI/ultrasound may be 
used to identify additional joints (include: temporomandibular, 
sternoclavicular, acromioclavicular, and others as reasonably expected in RA). 
 
1 large joint (shoulder, elbow, hip, knee, ankles)  0 
2–10 large joints   1 
1–3 small joints (MCP, PIP, MTP 2–5, thumb IP, wrist); large joints not 
counted  
2 
Does not include: DIP, 1st CMC, 1st MTP  
4–10 small joints (large joints not counted)  3 
<10 joints (at least one small joint) 5 
Serology (0–3 points) points 
Serology: Negative: ≤ULN (for the respective lab), Low positive: >ULN but 
≤3×ULN, High positive: >3×ULN 
 
Where RF is only available qualitatively, a positive result should be scored as 
'low-positive' for RF 
 
Negative RF and negative ACPA  0 
Low positive RF or low positive ACPA  2 
High positive RF or high positive ACPA  3 
17 
 
Continued Panel 5. 
         These criteria permit an earlier diagnosis of RA compared to previous ones. The 
following steps are suggested as an approach to the evaluation of patients with early RA 
(Panel 6).  
 
Panel 6. Approaches to early RA diagnosis. 
• Recognize the presence of inflammatory arthritis. 
• Exclude diseases other than RA or UA (undifferentiated arthritis) that present as an 
early inflammatory arthritis (e.g. SLE, psoriatic arthritis, or other spondyloarthropathy). 
• Estimate the risk of developing persistent or erosive irreversible arthritis in patients 
with RA or UA by using a combination of clinical features, laboratory tests and imaging 
techniques. 
Symptom duration (0–1 points) points 
Symptom duration refers to the patient’s self-report on the maximum 
duration of signs and symptoms of any joint that is clinically involved at the 
time of assessment. 
 
<6 weeks  0 
≥6 weeks  1 
Acute phase reactants (0–1 points)  
Normal CRP and ESR  0 
Abnormal CRP or abnormal ESR  1 
Normal/abnormal ESR/CRP is determined by local laboratory standards  
Score ≥6 is classification of RA                                                                Total: 
A score of 6/10 needs to be achieved from four domains including:  
Joint activity (0–5 points), serology (0–3 points), symptom duration (0–1 point), and 
acute phase   response (0–1 point). ACPA, anti-citrullinated protein/peptide antibodies; 
CRP, C-reactive protein; DIP, distal interphalangeal; ESR, erythrocyte sedimentation 
rate; MCP, metacarpophalangeal; MTP, metatarsophalangeal; RF, rheumatoid factor; 




2.2.5 Treatments of RA 
Nowadays, the optimal strategy to manage RA, accepted by most Rheumatologists, 
includes early detection, early diagnosis and early treatment. The goal of RA treatment is 
to suppress the underlying inflammation and hence reduce symptoms and prevent 
irreversible joint damage. Therefore, RA management encourages more dynamic use of 
medication (Guidelines, 2002). Treatment normally starts with a synthetic DMARD, 
typically methotrexate as soon as possible after diagnosis (Aletaha et al., 2010b). Other 
DMARDs such as  Leflunomide and  hydroxychloroquine can also be used (Ruderman, 
2012). Failure of or intolerance to these conventional synthetic DMARDs can allow the 
subsequent use of a biologic or targeted synthetic DMARD (Salt and Crofford, 2012).  
2.2.6 Synovitis of RA 
Synovitis is a key feature in RA which if untreated, this can lead to destruction of adjacent 
tissues including cartilage and bone. The arthroscopic appearance of inflamed RA 
synovium shows hypergenesis of synoviocytes and capillary vessels that form a pannus 
(Orr et al., 2017). Histologically, inflammatory cells including macrophages, neutrophils, 
and lymphocytes infiltrate intimal and sub-intimal layers (Tak et al., 1997).  The resulting  
pannus damages adjacent cartilage and bone, with ultimate destruction of the joint (Mullan 
et al., 2007) and destructive changes observed by imaging (Tak et al., 1997, Orr et al., 
2017, Van der Heijde, 1996). 
 
2.3 Heterogeneity of OA and RA synovitis 
2.3.1 Synovium 
Synovial joints are composed of a joint cavity, cartilage of adjoined bone and articular 
capsule. The synovial membrane/synovium comprises the inner layer of the capsule and 
contains an intimal layer and subintimal layer. The intimal layer is 20-40μm thick and 
borders the joint cavity. The subintimal layer, approximately 5mm thick is classified into 
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three types: areolar, adipose and fibrous (Figure 3A) (Prieto-Potin et al., 2015). The intimal 
layer of synovium is composed of two diverse cells: Type A and B (Figure 3B) 
(IWANAGA et al., 2000).  
          Type A/Macrophage-like synoviocytes (MLS) originate from monocytes or 
macrophages from the circulating bloodstream (Smith, 2011). They are CD168+ and 
CD68+ cells, with increased activity of non-specific esterase and they possess high 
expression of immunoglobin receptor FcRIIIa (Orr et al., 2017). Although MLS 
proliferation is low in the intimal synovium, these cells still have the ability of phagocytosis 
(Bartok and Firestein, 2010). Type B/Fibroblast-like synoviocytes (FLS) originate from 
local tissue to produce synovial fluid and its components. The synovium is responsible for 
supplying metabolites and oxygen to chondrocytes for producing cartilage through 
secretion of SF, together with removing metabolic waste, carbon dioxide and degraded 
matrix. Hyaluronic acid and lubricin, secreted by FLS, can diminish the friction among 
focal areas of articular cartilages. Abnormal synovium, usually caused by inflammation, 
cannot maintain the homeostasis of joint environment leading to loss of the joint function. 
A B 
  
Figure 3. Images of synovium layers and cellular types in the intimal layer of synovium, 
reproduced from the ectoderm. (A) Synovium two layers and their thickness (Prieto-
Potin et al., 2015). Scale bar: 100μm. (B) Electron-microscopic image of cellular types 
in the intimal layer of synovium (IWANAGA et al., 2000). ×2,800 magnification. A, 
type A synoviocytes; B, type B synoviocytes. 
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2.3.2 Low- and high-grade synovitis of OA and RA 
OA is an articular disease with low-grade synovitis with extensive publications have 
documenting synovial inflammation in  OA (De Lange-Brokaar et al., 2012, Lana and 
Rodrigues, 2019). In Hematoxylin and Eosin (HE) stained slides of OA synovium, the 
intimal layer contains hyperplasia of synoviocytes. Meanwhile, capillary proliferation is 
observed in the sub-intimal layer. Simultaneously, inflammatory cells infiltrate into the 
synovium of both OA and RA, and release cytokines to regulate local inflammation. 
Synovitis of OA is much less extensive than that found in RA, but greater than in normal 
healthy joints. 
2.3.3 Synovitis score of OA and RA 
         Synovitis evaluation systems are widely used to score the severity of synovitis in 
arthritis. The most popular is Krenn’s Scoring System that includes the thickness of the 
intimal layer, cells number in synovial stroma and inflammatory cells number (Krenn et 
al., 2006). Table 1 illustrates the synovitis comparison among control (C), OA and RA. It 
is noticeable that the synovitis score of OA (mean range 2-3) is higher than that of healthy 
controls (mean<1.5), but much less than in RA (mean>5). In the Prieto-Potin et al. study, 
the OA group was divided into two sub-groups: non-inflamed (score range 0-1) and 
inflamed (score range 2-3) OA (Prieto-Potin et al., 2015). Synovitis was not present in all 
OA patients, but was present at high grade in each RA specimen. 
2.3.4 Synovitis with infiltrated cells of OA and RA 
        The number of infiltrating inflammatory cells in normal control was less than in OA, 
which in turn was less than in RA. Most researchers report that the major cell type 
infiltrated into the synovium of both OA and RA were macrophages and T cells. Compared 
with infiltrated macrophages that infiltrated into the RA synovium, macrophages infiltrated 
into OA synovium possess higher ability to perform phagocytosis (Wood et al., 2019). 
Although T cells accumulated in the synovium of OA and RA, the CD4+/CD8+ T cell ratio 





Table 1. Summary of synovitis score and infiltrated cells in the sub-intimal layer in 
comparison of normal control (C), OA and RA. 
Sample 
(size) 







T cells in synovium: C: 4, 
OA: 6; RA: 16; 
B cells in synovium: C: 1, 
OA: 1, RA: 0; 
Macrophages in synovium: 






Arthroplasty HE, IHC 
Moderate/abundant 
mononuclear cells, few 
giant cells in synovium of 
OA and RA; 
No difference between OA 















T cells: C<OA<RA; 
B cells: C<OA<RA; 
Plasma cell: C<OA<RA; 
phagocyte: C<OA>RA; 
detritus-rich in OA and its 
synovium infiltrated with 
neutrophils and 























C: 1.38, OA: 2.6; RA: 6.0; 
More T cells, B cells and 
microphages infiltrate in 








Continued Table 1. 
Sample 
(size) 











C: 1.38, OA: 2.23, RA: 
5.74;  
Infiltrated cells:  
T cells: C: 27.7, OA: 67.2, 
RA: 552.9;  
B cells: C: 2.3, OA: 16.5, 
RA: 251.4; 
Plasma cells: C: 0.3, OA: 
23.3, RA: 625.5; 
Macrophages: C: 8.2, OA: 
























OrthA: 2, OA: 3, RA: 4;  
Infiltrated cells:  
T cells: OrthA: 13.2, OA: 
113.2, RA: 578.9;  
B cells: OrthA: 15.8, OA: 
18.4, RA: 384.2; 
Plasma cells: OrthA: 21.1, 
OA: 21.1, RA: 600.0; 
Macrophages: OrthA: 
48.0, OA: 30.0, RA: 
530.3. 











C/OANI < OAI <RA; 
Infiltrated cells:  
MGC+ synovium%: 
C/OANI < OAI <RA; 
MGC diameter: OA<RA; 










Continued Table 1. 
Types 
(size) 
Specimen Evaluation Findings Ref. 
Note: C is control; OrthA is orthropathy arthritis; OANI is OA with non-inflammation; 
OAI is OA with inflammation; MGC is multinucleated giant cells; # means controls from 
post-mortem (PM). 
 
         Similarly, the ratio of Th1/Th2 was higher in RA (6.1) than in OA (1.5) (Yudoh et 
al., 2000). B cells and plasma cells were the minority cell types in OA and RA synovium, 
and their numbers were greater in RA (Pessler et al., 2008a). Neutrophils were rarely found 
in OA, but were one of the most abundant cells in synovial fluid (SF) of RA (Tak et al., 
1997, Pessler et al., 2008b, Saito et al., 2002). When plentiful detritus existed in OA, 
neutrophils and multinucleated giant cells (MGC) would accumulated in the synovium 
(Oehler et al., 2002).   Natural killer (NK) cells and dendritic cells (DC) also were found 
in OA and RA synovium, but the numbers were lower than neutrophils and MGC (Pettit et 
al., 2001).  More and more highly active NK cells were detected in synovial fluid of RA 
(Yamin et al., 2019), while mast cells and adipocytes of synovitis were fewer in OA than 
RA (Gotis‐Graham and McNeil, 1997, Shanaj and Donlin, 2019).  
         Synovitis also is also detectable in other forms of inflammatory arthritis including 
psoriatic arthritis, juvenile idiopathic arthritis and Lyme arthritis (Moll et al., 2009, Collado 
et al., 2013, Jutras et al., 2019). 
 
2.4 Extracellular vesicles 
There has been an increasing interest over past decades in extracellular vesicles (EV) 
originating from various cells. EV are released from cells and are comprised of cellular 
membranes (including membrane proteins) together with plasma protein, nucleic acid, and 
carbohydrates. EV are considered as the transportable packages, transferring information 
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from donor cells to target cells. The physiological and pathological features of recipient 
and donor cells can be influenced during EV release and subsequent internalization. EV 
are vesicles with a phospholipid bilayer released by conserved methods from prokaryotes, 
eukaryotes and plant cells. Over the years, interest in EV in the literature has grown 
exponentially (this data website link is https://academic.microsoft.com/topic/2992929900), 
especially after 2012 (Figure 4). 
 
Figure 4. Publication and citation of EV related research and review papers from 2005 to 
2019. 
2.4.1 EV classification 
The EV family has been expanded from classically-defined EV (exosomes (Exo), 
microvesicles (MV), apoptotic bodies (AB)) to large oncosomes (released by cancer cells). 
The assembly mechanisms of these different family members are essentially different. 
Exosomes are produced by inward budding of cellular membrane to initially form 
endosomes, which then generate multivesicular bodies (MVB) to fuse with phospholipid 
membranes (Cocucci and Meldolesi, 2015). MVB are released by exocytosis into the 
intercellular space. Exosomes range in size from 50-100 nm. After appropriate stimulation, 
they are released by outward budding. Their diameter is 100/200-1000 nm. AB are 
produced by apoptotic cells and their size is 800-5,000nm. The diameter of oncosomes is 
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larger than other EV at approximately 20μm  (Crescitelli et al., 2013, Meehan et al., 2016). 
The different characters of Exo and MV are illustrated in Table 2. 
 
Table 2. Different and analogous properties of microvesicles and exosomes. 
Property  Microvesicles Exosomes 
Assembly manner Outward budding MVB 
Size (nm) 100-1,000 50-100 
Protein (membrane and plasma) High Low 
RNAs + Low 
DNA N/A N/A 
MVB exocytosis N/A High 
Releasing time Seconds Delayed 
Fusion with target cells + + 
membrane fusion with target cells + + 
Endocytosis by target cells + + 
Navigation of EV mixtures + + 
Diagnosis and therapy + + 
 
2.4.2 MV in OA and RA 
EV can be detected by electron microscopy (EM) and nanoparticle tracking analysis (NTA) 
SF of both OA and RA.  Isolated EV are composed of Exo and MV and the mean of total 
EV protein in OA was 0.14mg/ml which was less than RA (0.88mg/ml) (Gyorgy et al., 
2012). SF EV from OA and RA contained abundant proteins originating from cellular 
plasma, such as albumin, actin, and myosin, and also clusterin in SF of OA and RA patients 
(Gyorgy et al., 2012) . However, protein types and compositions were not merely different 
in OA and RA (Gyorgy et al., 2012).  It was found that CD3 and CD8 were expressed at 
significantly higher levels in RA EV than in OA EV. While Annexin V, CD4, CD14, CD19, 
CD41a and RANK, RANKL were found at higher levels in RA EV than in OA EV, these 
differences were not significant (Gyorgy et al., 2012). It was also found that MV were 
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generated by granulocytes and monocytes in RA SF, platelet-derived MV predominated in 
RA plasma. Other investigators have reported that platelet-derived MV are increased in RA 
blood and correlated positively with RA disease activity score 28 (DAS-28)  (Knijff-
Dutmer et al., 2002). In contrast, Headland et al. reported that MV from RA SF expressed 
higher levels of Annexin A1, CD66b, CD14 and CD3 than plasma MV. In fact, annexin 
A1+ MV also expressed the neutrophil marker CD66b indicating that the MV were 
generated from neutrophils in RA patients  (Headland et al., 2015). 
2.4.3 MV impact on FLS 
In an in vitro study, MV generated from T cells and monocytes could increase expression 
of MMP-1, 3, 9 and 13 by FLS, regulated in a time-dependent manner (Distler et al., 2005a) 
These MV also up-regulated cytokines (IL-6, 8) and monocyte chemoattractant protein 
(MCP) 1 and 2 of FLS derived from OA and RA synovial membranes. When FLS were 
pre-treated with receptor antibodies to IL-1β and TNFα receptor antibodies, MV still could 
promote MMP1 and IL-6 expression (Distler et al., 2005a). Furthermore, T cells and 
monocytes derived MV elevated cellular mediators (CXCL-1, CXCL-2, CXCL-3, etc.) 
which could pro-angiogenic function in FLS to improve hypervascularity of the synovium. 
In addition, MV either up-regulated these mediators and improve immigration of the 
endothelial cells as well (Reich et al., 2011).  
 
2.5 Neutrophil-derived microvesicles (NDMV) 
2.5.1 Abundant NDMV in inflammatory sites 
Although the lifespan of neutrophils is relatively short (Elbim et al., 2009), they are still 
the most abundant leukocyte type in circulation and are involved in innate immunity 
(Summers et al., 2010).  NDMV are present in low concentrations in healthy blood/serum, 
but increase in inflammation (L Johnson et al., 2014). The majority of MV in the venous 
blood in healthy controls are platelet-derived, but NDMV will predominate at the foci of 
inflammation and infection. For instance, NDMV levels were increased 14 fold higher in 
blister induced by Cantharidin compared to levels in serum, but the number of neutrophils 
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was 10 times less in blisters than in blood (Daniel et al., 2006, Dalli et al., 2013).  
2.5.2 Proteins of NDMV 
The NDMV diameter range is 100 to 1,000nm, as identified by EM, Nanoparticle Tracking 
Analysis (NTA) and flow cytometry. The common proteins expressed on NDMV include: 
phosphatidylserine and annexin A1 (Dalli et al., 2008). NDMVs also express identical 
membrane proteins as neutrophils: CD11b, CD62L, CD66b, CD18, CD55 and Fc receptors 
and also several neutrophil granule-proteins (Gasser et al., 2003, Dalli et al., 2013, 
Headland et al., 2015).  
2.5.3 Stimulants for NDMV generation 
NDMV can be generated in vitro by treatment with various agonists, cytokines, pathogens 
and proteins, such as Mycobacterium tuberculosis, Staphylococcus aureus, fMLP, LPS, IL-
8, TNF-α, anti-neutrophil cytoplasmic antibody (ANCA), nitric oxide, as well as ultraviolet 
light (Hong, 2018). Table 3 lists that various reagents that have been used to stimulate 
neutrophils to generate microvesicles after varying exposure times, concentrations and 
temperatures. Differential centrifugal force is frequently used to isolate microvesicles. 
Table 3. Summary of used reagents, concentration and times to stimulate neutrophils to 






Reagent Conc. Time 
1 20×106  TNFα 50ng/ml 20min 
1) 13,000g, 4 oC, 
2min; AB.  
2) 20,000g, 4 oC, 
30min; MVs. 




2 106  
fMLP 0.5-1µM  
20-
30min 1) 13,000g, 4 oC, 
10min; CD. 
2) 100,000g, 4 oC, 
60min; MVs. 
(Finkielszte
in et al., 
2018) 
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Reagent Conc. Time 
3 20×106  
fMLP 1µM  20 min 
1) 3,000g, 4 oC, 
10min; CD. 




PMA 200nM  20 min 
latrunculin 





4 10×106  PMA 10 nM  30min 
1) centrifugal 
filter devices (10 
kDa MWcutoff).  














2) filtered fraction 
was sedimented 
again (15,700g, 4 
oC, 10min; MV). 
(Timar et 
al., 2013) 
PMA 100nM 20min 













S aureus 108/mL 20min 
6 20×106  









IL-8 50 ng/ml 2h 






0.2 µm filtration 
and resuspended 




PMA 1 µM 2h 
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Reagent Conc. Time 
8 20×106  














9 10×106  
calcium 
ionophore  
2 μM 20 min 
100,000g for 45 




PMA 200 nM 30 min 
LPS 10 μg/ml 2h 
UV N/A 20min 
10 20×106  fMLP 1µM 20min 








11 20×106  fMLP  1µM 20min 




12 5×106  TNFα 2 ng/ml  15min 
5000g, 4 oC, 
45min to remove 





13 10×106  
M. 
tuberculos










14 106 PMA 10nM 5min N/A 
(Gonzalez-
Cano et al., 
2010) 
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Reagent Conc. Time 



























17 10×106  














18 10×106  








ionomycin 5µM 20min 
PMA 10 nM 20min 
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1) 1.2 µm pore 
filter 








1) 500g, 5min;  






apoptotic bodies (AB); microvesicles (MV); exosomes (Exo); cell debris (CD); 
ultraviolet light (UV). 
 
2.5.4 Effect of NDMV on target cells 
NDMV can regulate cytokine and chemokine expression of target cells, but the precise 
response depends on the properties and functions of the recipient cells (L Johnson et al., 
2014). NDMV stimulated the Mitogen-activated Protein Kinase/c-Jun N-terminal kinases 
1 (MAPK/JNK1) signaling pathway of endothelial cells to produce IL-6, IL-8, MCP-1, 
adhesion molecule (Mesri and Altieri, 1999, Hong et al., 2012a). It has alos been reported 
that NDMV interacted with CD18 of endothelial cells to upregulate ICAM-1 and reactive 
oxygen species (ROS) (Hong et al., 2012a). Moreover, NDMV upregulate tissue factors to 
promote a procoagulant effect (Mesri and Altieri, 1999). 
         Previous studies have reported that NDMV can play an anti-inflammatory role. For 
endothelial cells, NDMV were able to decrease NF-κB, CCL8 and STAT1 levels in 
endothelial cells to inhibit pro-inflammatory responses (Dalli et al., 2013). NDMV could 
down-regulate inflammatory effects of macrophages via inhibiting phagocytosis and NF-
κB activation, as well as promoting expression of lipid resolving factors (Eken et al., 2010). 
Other cytokines produced by macrophages also were down-regulated by NDMV, such as 
IL-8 and TNFα, but NDMV increased the expression of TGF-β1 that has an anti-
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inflammatory effect on macrophages (Gasser and Schifferli, 2004). Eken et al. 
demonstrated that NDMV could inhibit the macrophage inflammatory response via the 
PI3K/AKT pathway and MerTK (Mer-receptor tyrosine kinase) pathways (Cumpelik et al., 
2016, Eken et al., 2010). Additionally, NDMV can also modulate phagocytotic function of 
monocyte-derived dendritic cells (DC) and up-regulate their TGF-β1 expression (Eken et 
al., 2008). IFN-γ and TNFα expressed by NK cells was blocked by co-culture with NDMV, 
despite TGF-β1 levels increasing in culture medium (Pliyev et al., 2014). Furthermore, 
neutrophil adherence and erythrocyte aggregation can be affected by NDMV through their 
expressed  Annexin A1 and complement receptor 1 (Gasser and Schifferli, 2005, Dalli et 
al., 2008). NDMV interact with MerTK and Formyl Peptide Receptor (FPR)-2 of 
macrophage through their delivered phosphatidylserine and Annexin A1.  
2.5.5 Relevant studies about NDMV effects on OA and RA 
Exogenous NDMV are capable of decreasing IL-8 and prostaglandin E2 expression in 
chondrocytes (Headland et al., 2015). The consequences of this may be that inflammation 
is decreased and cartilage would be protected and restored, as well as gradually increasing 
the extracellular matrix of cartilage (Headland et al., 2015). The same research group 
identified that TNFα induced NDMV could modulate macrophages to affect FLS of RA. 
The TGF-β increasing of LPS induced macrophages, was enhanced by NDMV, while in 
contrast, up-regulation of cytokines (IL-1β, IL-10, IL-12), MHC II and CD86 of LPS 
induced macrophages was inhibited by NDMV. After FLS were co-cultured with NDMV-
activated macrophages, the levels of IL-6, TNF-α, MCP-1 and CD55 were all decreased 
(Rhys et al., 2018).  
 
2.6 Summary 
Low grade inflammation characterizes many forms of OA but the mechanisms responsible 
are not fully defined. NDMV have shown anti-inflammatory potential in some situations, 
but their role in down-regulating inflammatory responses of FLS from OA patients has not 
been reported. This thesis, therefore, aims to establish the effects of NDMV on FLS 
function and viability, and in particular to determine if they can down-regulate chemokine 
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Chapter 3. MATERIALS AND METHODS 
Ethics 
The thesis referred to research about human bio-specimens and personal information, 
therefore, this research proposal was submitted to the Institutional Review Board (IRB) of 
Faculty of Medicine, Chulalongkorn University. Ethics committee approved the proposal 
which was annotated as 565/59 to allow us to collect tissue and blood from patients and 
healthy volunteers. All processes were conducted in compliance with the guidelines of 





Part A: FLS Culture and Testing 
3.1 OA patients 
The diagnosis of OA was based on the ACR criteria by surgeons from Department of 
Orthopaedics, Chulalongkorn Memorial Hospital. Patients with knee trauma, operation or 
history of other chronic inflammatory or immunological diseases were not included in this 
study. Fifteen knee OA patients were recruited to donate their synovium at the time of total 
knee replacement (TKR). 
         Synovium samples were saved in sterile collection bottles surrounded by ice and 
carried into cell culture room within 1h. Their age ranged from 58 to 81 with an average 
age of 70.33±1.81 (mean ± S.E.) years. There were 12 female patients with knee OA 
(~80%), and 3 knee OA patients were male (~20%). The average of Body Mass Index 
(BMI) was 25.56±0.92kg/m2 over than the overweight criteria of 25 kg/m2. BMI minimum 
of knee OA patient is 20.08 kg/m2 of a female OA patient and maximum is 32.65 kg/m2 
of a female patient also. Two patients KL scores were highest to 4, but the severity of 10 
patients were scored to 2. All patients bore different levels of pain from 3 to 9. Their pain 
average was 5.33±0.53 kg/m2. Beside KL grading system was used to evaluate severity of 
knee OA by radiographic and symptomatic examination, Knee injury and Osteoarthritis 
Outcome Score (KOOS), Indices of Severity and disease activity for Osteoarthritis (ISOA) 
and Western Ontario and McMaster Universities Arthritis Index (WOMAC) were also 
utilized to evaluate pain, symptoms and joint function. The average of these three knee OA 
















KOOS ISOA WOMAC 
1 72 F 20.08 4 5 25.00 17 105.00 
2 69 F 26.64 3 3 25.00 15 115.59 
3 65 M 29.05 3 6 43.75 10 253.82 
4 58 F 25.10 2 5 31.25 11 208.53 
5 64 F 27.06 2 3 12.50 15 168.68 
6 61 F 24.09 2 3 18.75 14 148.97 
7 73 F 23.11 2 4 18.75 14 155.44 
8 77 F 22.06 3 9 12.50 13 202.06 
9 77 M 21.33 4 3 12.50 17 52.21 
10 65 F 25.24 2 8 12.50 14 121.62 
11 73 F 27.34 2 7 12.50 13 160.88 
12 81 M 22.77 2 7 37.50 11 155.29 
13 67 F 25.68 2 4 37.50 14 201.62 
14 81 F 32.65 2 8 37.50 13 155.00 
  15 72 F 31.20 2 5 25.00 8 147.21 
Note: KL represent the score by Kellgren and Lawrence grading system; KOOS is knee 
injury and osteoarthritis outcome score; ISOA is indices of severity and disease activity 
for osteoarthritis; WOMAC presents Western Ontario and McMaster Universities 





3.2 Explant tissue culture 
Synovium samples were moved from the tissue bottle to a sterile dish and washed with 
normal saline at least 3 times to remove residual blood and to identify fat tissue (yellow) 
and synovium (white) in aseptic conditions (Figure 5A). All fat tissue was removed and 
only white tissue left by the scalpel or scissors. White synovium was dissected into 2-3mm 
sections. Each section was picked with syringe needle and placed into bottom of a flask. 5-
10 drops of synoviocyte culture medium (DMEMα and 10% FBS, 100U/ml penicillin G, 
100mg/ml streptomycin and 2.5mg/ml amphotericin B) were added gently on each section 
to avoid tissue debris floating in medium (Figure 5B & D). The flask was places in a 37 °C 
incubator (Forma Steri-Cycle i160 CO2 Incubator, Thermo Scientific, Massachusetts, US) 
with 5% CO2 and culture medium was changed carefully every 3 days by using 1ml syringe. 
After 14 days of tissue culture, massive single cells were observed growing away from the 
tissue sections and attached to the flask (Figure 5C). 5ml PBS was filled into the flask twice 
to wash away all tissue debris. Next, 0.25% trypsin (2.5ml) was added to the flask and 
incubated for 5min. Culture medium (2.5ml) was added to cease the trypsinization. Cell 
suspension was centrifuged at room temperature by 250g for 10min. The cell pellet was 
resuspended into 5ml culture medium, and then transferred into the flask to culture in 37°C 
incubator with 5% CO2 atmosphere. Culture medium was changed every 3 days and cells 
were split until passage 4 for further usage. 
         The synoviocytes culture medium was composed of DMEMα and 10% FBS, 











Figure 5. Process of primary synoviocytes culture by explant culture method. (A) The 
synovium (white or pink) was identified from the adipose tissue (yellow) after washing 
with normal saline. (B & D) The synovium debris were seeded on the bottom of the flask 
and added in a few drops of culture media. (C) Single cells started to secede from tissue 







3.3 Dispersed cell culture 
Under aseptic conditions, synovium tissue in sterile bottle was transferred to a plastic dish 
and washed 3 times by PBS to remove residual blood from the tissue. Fat tissue was 
discarded as much as possible and white synovium was minced by scalpel or scissors. The 
synovium mince was transferred into a centrifuge tube filled with 1ml 0.25% trypsin and 
incubated for 15min at 37°C and 5% CO2 atmosphere (Figure 6A). The ratio of mince 
volume to trypsin volume was 1:10. Subsequently, this mixture was centrifuged at 100g 
for 5min to remove supernatant and trypsin (Figure 6B). Pelleted mince was digested in 
1ml HBSS with collagenase (1mg/ml) for 2h at 37 °C with 5% CO2 (Figure 6C). The 
centrifuge tube was shaken every 15min for 30s. Then the mixture was centrifuged at 250g 
for 5min to discard supernatant and collagenase (Figure 6D). Pelleted mince was suspended 
in 5ml culture medium and filtered through 100µm nylon mech to removed tissue blocks. 
Collected single cells were cultured in a flask and non-adherent cells were removed by 
culture medium changes on day 1, 3 and 7. Attached cells were cultured and passaged 











Figure 6. Process of primary synoviocytes culture by dispersed cell culture method. (A) 
The minced synovium was digested with 0.25% trypsin. (B) Trypsin digested minces were 
centrifuged into tissue pellets. (C) The second enzyme, 1mg/ml collagenase, was added to 
digest tissue pellets. (D) Collagenase digested pellets were centrifuged to pellet dispersed 






3.4 Cells confluence measurement 
Cells are commonly sub-cultured when their confluence achieves 80-90%.  Cell confluence 
was measured via captured pictures by invert light microscopy and analysed by ImageJ. 
The time for cells to proliferate to 85% confluence was recorded and analysed. Cells from 
explant and dispersed cell cultured were seeded in tissue culture flask T25 (ThermoFisher, 
NY, US) and cells images were captured by light microscope (Eclipse TS100 Nikon, Japan) 
with 4-fold objective (Figure 7A). ImageJ and PHANTAST FIJI plugin were used to 
measure cell confluence. The raw image was opened in File option and converted into 32-
bit grey image in the function menu: Image-Type-32bit. The plugins of PHANTAST was 
opened in Plugins-Segmentation-PHANTAST. In Segmentation Parameters window, 
sigma and epsilon of local contrast thresholding was set as 4 and 0.02. In output options, 
compute confluency of measurements was selected, as well as new mask image (Figure 
7B) and selection overlay on original image (Figure 7C) of Image Output were ticked in 
checkbox. The new mask image was used to analyse by click on “OK”. The Result Table 







Figure 7. Cell confluency measured with 
ImageJ and PHANTAST plugin. (A) show 
original image captured by phase contract 
light microscope. (B) The new mask 
image was obtained by PHANTAST 
plugin, the white area represents cellular 
confluency and the black colour is area 
without cells. (C) The merged image of 
original image (A) and the image of 
acellular adhesion area (B), the yellow 










3.5 Mycoplasma contamination detection by PCR 
Cultured cells were directly harvested with plastic scrapers in culture media (without 
removing culture media or washing cells). Cells and media were moved into centrifuge 
tube and boiled for 10min in the water bath. The cell suspension was centrifuged at 1,500g 
for 5min at 4°C. 4μl supernatant was added into a PCR reaction system which was prepared 
according to the manufactures protocol (mycoplasma PCR detection kit, HuaBio, 
Hangzhou, China).  
         The components of reaction mixture (25μl) consisted of 20μl PCR solution, Taq 
enzyme solution 1μl and sample supernatant or positive or negative control solution. The 
mixtures were prepared in PCR tubes (Thermo Scientific, Massachusetts, US) which were 
placed in a PCR Mastercycler (Eppendorf, CA, US). The conditions for PCR amplification 
was conducted according to the manufactures protocol as follows: initial denaturation at 
94 °C for 5min, 30 amplification cycle at 94 °C for 30s, 56°C for 30s, 72°C for 45s, and 
final extension at 72°C for 5min. PCR products were load into wells of 1% agarose gel for 
electrophoresis for 30min at 120V. Gels were stained with 5% ethidium bromide in water 







3.6 Cell growth curve 
0.25% trypsin was used to harvest passage 1 and 4 cells of primary culture. Cell 
concentration was diluted into 105cell/ml with synoviocyte culture medium. 100μl cell 
suspension (1,000 cells) was seeded into each well of a 24-well plate and replenished with 
culture medium to 1000μl. When cells were cultured in the incubator for each 24h, cells of 
one well would be harvested by adding 500μl 0.25% trypsin. Digestion was stopped by 
supplementing with 500μl culture medium. 5μl cells suspension and 5μl trypan blue 
(volume ratio 1:1) were mixed and pipetted gently for counting cell number on the 
hemocytometer chamber. Three wells were used to calculate cell numbers for each day. 
Cell culture continued for 8 days and the culture medium was replaced every 3 days.  
         To characterize the growth of diploid primary cells, population doubling time was 
calculated in P1 and P4 from explant culture and dispersed cell culture. The following 






Equation 1. Doubling time of 
cells population. 
 
DT is doubling time of primary cells. 
T is cell cultured time, 8 days or 192 hours. 
𝑁𝑡 is the cell number after 192 hours culture.  




3.7 Cell cycle phase 
Cells from passage 1 and 4 of primary culture were harvested with 0.25% trypsin. After 
centrifuging cells suspension at 250g for 5min, 106 cells were resuspended in ice-cold PBS 
with 70% ethanol (3ml) and vortexed for 3s. Then cells were incubated at 4°C for 15min 
in fridge. Cells were pelleted by centrifugation at 250g for 5min and washed twice by cold 
PBS. Washed cells were resuspended in 500µl PI-solution that consisted of PBS, 50 µg/ml 
PI, 0.1 mg/ml RNase A and 0.05% Triton X-100. The mixture was incubated for 40min at 
room temperature (RT). After refilling 3ml PBS to stop staining, cells were centrifuged at 
250g for 5min again. Cells pellet was resuspended in 1000μl PBS to be ready for flow 
cytometry analysis: BD LSR II (San Jose, CA, USA). PI fluorescent signal was detected 
with in the channel of PE/Texas Red. 
 
3.8 Flow cytometry for fibroblast CDs expression 
Primary synoviocytes from passage 1 and 4 were harvested by adding 0.25% trypsin (2.5ml) 
for 5min, and then supplimented with 2.5ml synoviocyte culture media to stop digestion. 
After cell suspension was centrifuged at 900g for 3min, cell concentration was adjusted to 
be 107cell/ml with culture medium. 100μl cells suspension was moved into 1000μl PBS 
with 10% FBS and centrifuged at 900g for 3 min. Cells pellet was resuspended in 100μl 
PBS supplemented with 10% FBS. Four single-labels antibodies (FITC-CD90, FITC-
CD64, PE-CD55, APC-CD11b) with volume of 5μl were respectively added into cell 
suspensions. After brief vortex, cell suspensions with anti-human CDs were incubated at 
RT in the dark for 30min. Subsequently cells suspension was replenished PBS with 10% 
FBS up to 1000μl and centrifuged at 900g for 3min. Cell pellets were resuspended in 500μl 
PBS with 10% FBS followed by 500μl PBS with 4% paraformaldehyde (PFA) to fix cells 
at RT for 15min in dark. Cell suspensions with fixing solution were centrifuged again to 
acquired cells pellet which were resuspended in 1000μl PBS with 10% FBS to be ready for 





Part B: Neutrophils Isolation and Functional Assays 
3.9 Healthy volunteers 
Peripheral blood from 10 healthy volunteers was collected into lithium-heparin tubes 
(Greiner Bio-One, Chonburi, Thailand). Random urine specimens were collected in 5ml 
urine containers by volunteers, then stored at 4oC for laboratory testing. The urine and 
blood characteristics of all volunteers are summarized in more detail in Table 5-7. In 
urinalysis, all volunteer urines were clear and light yellow. The value of urine pH ranged 
from 5.5 to 7.5. The specific gravity of one urine was 10.21 higher than normal reference 
maximum. The protein, glucose, ketones, bilirubin, urobilinogen, nitrite, blood and 
leukocyte in all urine were normal. In blood chemical examination, 3 volunteers were 
found to have abnormal levels of cholesterol, triglyceride and alkaline phosphatase, but 
they did not complain any discomfort or signs and physicians did not find any clinical 
syndromes. All volunteers were normal in the hematological examination. 
 
Table 5. The urinalysis of volunteers who donated their whole blood. 




pH 5.5 7.5 6.0 5.6 6.4 5.0-8.0 
Specific 
Gravity 
1.008 1.028 1.017 1.014 1.021 1.015-1.025 
Note: The urea of all volunteers was yellow and clear. It was negative in protein, glucose, 
ketones, bilirubin, urobilinogen, nitrite, blood and leukocyte (esterase) of all volunteers. 
And the number of their RBC (/HPF) and WBC (/HPF) in urea were 0-3, epithelial cell 
(/HPF) was 0-2, bacteria (/HPF) were none, rare or few. The casts (/LPF), crystal (/HPF) 






Table 6. The blood chemicals tests of blood-donating volunteers. 




Uric Acid (mg/dL) 3.4 5.9 4.8 4.4 5.3 2.6-6.0 
Cholesterol (mg/dL) 110.0 202.0 168.6 149.3 187.9 <200 
HDL (mg/dL) 45.0 85.0 64.3 55.4 73.2 >40 
LDL (mg/dL) 94.0 155.0 124.1 112.2 136.0 <160 
Triglyceride (mg/dL) 35.0 234.0 100.8 65.9 135.7 45-150 
AST (U/L) 18.0 26.0 21.1 19.8 22.4 5-35 
ALT (U/L) 10.0 24.0 18.1 15.0 21.2 0-40 
ALP (U/L) 41.0 100.0 76.0 65.2 86.8 30-120 
FBG (mg/dL) 82.0 99.0 92.4 89.3 95.5 65-100 
BUN (mg/dL) 7.0 18.0 12.7 10.7 14.7 8-20 
Creatinine (mg/dL) 0.6 1.0 0.8 0.7 0.8 0.5-1.0 
eGFR (mL/min) 86.5 111.1 100.6 96.6 104.6 >60 
fasting plasma glucose 
(mg/dL) 
71.0 98.0 83.9 78.8 89.0 70-99 
alkaline phosphatase 
(U/L) 
45.0 121.0 104.1 91.0 117.2 40-120 
CK-MB (U/L) 13.0 23.0 19.3 17.4 21.2 0-24 
sodium/Na(mmol/L) 136.0 145.0 139.4 137.6 141.2 136-145 





Table 7. The haematological tests of blood-donating volunteers. 




red cell (106/μl) 3.7 5.1 4.4 4.1 4.7 3.5-5.5 
hemoglobin(g/dl) 11.5 15.6 13.7 12.8 14.6 12-16 
platelet (103/ μl) 156.0 433.0 289.5 232.4 346.6 150-450 
white blood (103/μl) 6.2 10.3 7.8 6.9 8.6 4.5-11.0 
neutrophils % 44.2 69.5 59.7 54.8 64.6 40.0-70.9 
neutrophils (103/μl) 2.9 7.1 4.7 3.9 5.4 1.8-7.8 
lymphocytes % 23.2 41.2 34.1 31.0 37.3 22.2-43.6 
lymphocytes 
(103/μl) 
1.8 3.4 2.6 2.3 2.9 1.0-4.8 
monocytes % 3.3 6.8 4.9 4.2 5.6 0-7.3 
monocytes (103/μl) 0.2 0.6 0.4 0.3 0.4 0-0.8 
eosinophils % 1.9 3.5 2.8 2.5 3.1 0-4.1 
eosinophils (103/μl) 0.12 0.35 0.22 0.18 0.27 0-0.45 
basophils % 0.1 1.3 0.9 0.6 1.2 0-1.8 
basophils (103/μl) 0.0 0.1 0.1 0.0 0.1 0-0.2 
prothrombin time (s) 9.9 13.9 12.0 11.3 12.7 10.0-14.5 






3.10 Neutrophils isolation 
Blood of 50ml was layered over an equal volume of Polymorphprep (Axis-Shield, Oslo, 
Norway) reagent and centrifuged at 500g for 30min at 25°C. Peripheral blood mononuclear 
cell (PBMC) layer was removed after centrifugation, polymorphonuclear (PMN) 
leukocytes were collected by pipette, washed with RPMI 1640 medium (Gibco, NY, US) 
and centrifuged to remove reagents and platelets. Contaminating erythrocytes were lysed 
in red blood cell lysis buffer (Roche, Mannheim, Germany) for 3min in the dark. After 
centrifugation at 400g for 3min, pelleted neutrophils were resuspended in RPMI 1640 with 
5% vesicle-free serum to give a concentration of 2×107 cells/ml for further experiment and 
subsequent preparation of microvesicles (Figure 8). Each volunteer donated blood for each 
independent experiment. 
        Vesicle-free serum was prepared by ultra-centrifugation of human AB serum (EMD 
Millipore, MA, US) at 200,000g for 2h at 4°C. The supernatant was retained while the 








Figure 8. The progress of PMN isolation by polymorphprep. (A) Layer peripheral blood 
onto polymorpheprep solution. (B) The blood was separated into 6 layers: plasma, 
monocyte layer, solution layer, PMN layer, solution layer and erythrocytes layer after 
centrifugation. (C) The PMN layer was gathered and resuspended by RPMI 1640 medium, 
then centrifugated to obtain the cell pellets. (D) The supernatant was removed and red 
blood cell lysis buffer added. (E) Erythrocytes were lysed for 3min. (F) After centrifugation, 





3.11 Cytospin and wright staining for neutrophils purity 
Freshly isolated neutrophils (100,000 cells) were resuspended in 200uL PBS with 10mM 
EDTA and removed to cytospin funnel (Tharmac, Germany). After centrifugation 50g for 
5min at RT, the glass slide was allowed to air dry for 2min. Wright’s solution (Merck, 
Wright’s eosin methylene blue solution) was used to stain cells for 5min, before rinsing 
with deionized water twice. Dry glass slides were placed on light microscope (Nikon, 
Upright Microscope Eclip 50i) to count neutrophil amount and calculate purity. 
 
3.12 Flow cytometry for neutrophils purity 
Fresh isolated neutrophils (cell concentration 2×107 cells/ml) 2.5μl was suspended in 50μl 
PBS with 5% FBS. An equal volume of 4% paraformaldehyde in PBS was added for 15min 
at RT in the dark. After centrifugation with 900g for 3min, the supernatant was discarded 
and the cell pellet was resuspended in 200μl PBS with 5% FBS. Cells were analyzed by 
flow cytometry: BD LSR II (San Jose, CA, USA).  The trigger of flow cytometry was set 
on the SSC. The used voltage of photomultiplier tube was set on 630V and trigger threshold 
was set on 0. The noise background was adjusted with deionized water by technicians. 
 
3.13 Transwell assay 
5g poly-2-hydoroxyethyl methacrylate (poly-HEMA) (Sigma-Aldrich, Missouri, US) was 
dissolved in 100ml of 95% Ethanol at 65°C overnight to obtain 50mg/ml ploy-HEMA 
solution. To coat the lower chamber, each well of a 24-well plate was filled with 200μl 50 
mg/ml poly-HEMA and incubated overnight at RT. The Millicell hanging cell culture insert 
with 3.0μm pore size was settled in each well, then both upper and lower chambers were 
washed with PBS twice. 800μl RPMI 1640 medium with 10-8mol/L N-Formyl-L-
methionyl-L-leucyl-L-phenylalanine (fMLP) was added into each lower chamber. After 
the upper chamber was inserted in lower chamber for 5min, 200μl RPMI 1640 medium 
with 5×106cells neutrophils was added into upper chamber. The plate was incubated in for 
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90min with 5% CO2 atmosphere at 37°C. In the lower chamber, 800μl RPMI medium was 
gently aspirated several times and removed to new tube which is replenished 200μl RPMI 
medium to achieve 1000μl in total volume. The sum of migrated neutrophils was counted 
by hemocytometer (Bright-Line Hemacytometer, Sigma Aldrich, Missouri, US). 
 
3.14 Flow cytometry for CD11b and CD62L expression 
Neutrophils (2×107cells/ml) were incubated in the absence or presence of 50ng/ml TNFα 
for 20min in 5% CO2 atmosphere at 37°C. 2.5μl cells were removed and resuspend in 100μl 
PBS containing 5% FBS. After centrifuging at 900g for 3min, the cell pellet was flicked 
and resuspended in 10μl PBS with 5% FBS. Two single-label antibodies (1μl each APC-
CD11b and PE-CD62L) were mixed into cell suspension to achieve a working 
concentration. After vortex, cells suspensions with anti-human CDs were incubated at RT 
in dark for 30min. Cell suspension was replenished with 100μl PBS/5% FBS and 
centrifuged at 900g for 3min. Cell pellets were resuspended in 50μl PBS/10% FBS and an 
equal volume of 4% paraformaldehyde was added to fix cells at RT for 15min. Cells 
suspension with fixing solution was centrifuged 900g for 3min to acquired cells pellet 
which was resuspended in 200μl PBS/5% FBS to be ready for flow cytometry analysis. 
 
3.15 Luminol-amplified chemiluminescence assay 
Neutrophils (2×107cells/ml) were incubated in the absence or presence of 50ng/ml TNFα 
(to prime cells) for 20min in 5% CO2 atmosphere at 37°C. After prepared master mix of 
160μl was added in each wells of 96-well white plates (the master mixture included: 
158.8μl HBSS, 1μl luminol with finial conc. of 10μM and 0.2μl stimulus of fMLP with 
finial conc. 1μM or PMA with finial conc. 100ng/ml), 40μl of the primed-cell suspension 
was added to the plate quickly. The plate was transferred to the ready luminometer which 
could read plate every 0.7min as soon as possible. Chemiluminescence was measured and 




3.16 PI-Annexin V assay 
FITC Annexin V Apoptosis Detection Kit with propidium iodide (PI) (Biolegend, San 
Diego, CA) was used to conduct cells apoptosis assay. The 50ng/ml TNFα treated and 
untreated neutrophils (conc. 2×107 cells/ml) of 25μl were centrifuged at 900g for 3min and 
supernatant discarded. After pelleted cells were washed with cold PBS/10%FBS of 300μl, 
cells were resuspended in 100μl Annexin V binding buffer in 5ml tube. The cell suspension 
was added with 5µL FITC Annexin V and 10µL PI solution sequentially to incubate 15min 
at RT in the dark. Stained cells suspension was replenished with 400µl Annexin V binding 
buffer. Cells were captured and analyzed by flow cytometry: BD LSR II (San Jose, CA, 
USA). Annexin V signals were recorded on FITC channel and PI signals were captured on 
PE-Texas Red channel. Untreated neutrophils without staining was set as control cells of 




Part C: NDMV Isolation, Purification and Properties 
3.17 NDMV releasing and isolation 
Freshly isolated neutrophils (2×107 cells/ml) were stimulated with recombinant human 
TNFα (50ng/ml, Biolegend) for 20min at 37°C. Neutrophils and media were centrifuged 
at 4400g for 15min at 4°C to remove neutrophils. Thereafter, supernatant was centrifuged 
again at 13,000g for 2 min at 4°C to remove platelets. NDMV were pelleted by ultra-
centrifugation at 100,000g for 60 min at 4°C. Microvesicle pellets were re-suspended in 
100μl sterile particle-free PBS (0.02μm filtered), used fresh or frozen at -80°C until using 
for microRNA sequencing. 
 
3.18 Electron microscopy assay 
Pelleted NDMV were fixed for 3h in PBS with 2% glutaraldehyde and 2% 
paraformaldehyde (PFA), then examined by transmission electron microscopy of negative 
staining and scanning electron microscopy to ascertain extracellular vesicles morphology 
and diameter. TEM copper grid was floated on 10μl NDMV mixture for 10min, 1×PBS 
droplet and deionized water was used for washing in turn. The NDMV attached grid was 
floated on 10μl uranyl acetate and lead citrate to stain for 1min. Eventually, this TEM grid 
was imaged by JOEL JEM-1400 Plus TEM operated at 80-100kV (JEOL, Peabody, US).  
         For SEM examination, 5μl NDMV mixture was added on to silicon chips, which was 
dehydrated with series solvents for each 5min: 100% acetone, 100% ethanol and deionized 
water. Then the samples were conducted with critical point drying and mounted on a SEM 
stub which was sputter-coated with 40nm gold-palladium alloy. Lastly, samples were 
observed with a JEOL JSM-7610F SEM operated at 25-50 kV (JEOL, Peabody, US). 
 
3.19 Nanoparticle tracking analysis (NTA) 
The size distribution and particle concentration of NDMV were identified by using a 
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NanoSight NS300 (Malvern Panalytical, Malvern, UK) configured with an advanced 
sCMOS (scientific complementary metal-oxide-semiconductor) camera and a 405nm laser. 
The fresh NDMV were diluted 1000 times in particle-free PBS to reach a recommended 
concentration range from 106-109 particles/ml. High sensitive camera recorded NDMV 
Brownian motion in 60s length video for 5 times with camera level 15 under constant flow 
by syringe pump (flow rate=50) at 25°C. Those successive videos were analyzed 
automatically on Nanosight NTA 3.1 Software Build 3.1.54 at detective threshold 3. For 
other settings, viscosity was set to “water”, blur size and max jump distance were 
“automatic”. Five samples were analyzed by NTA. 
 
3.20 Flow cytometry of surface protein expression in NDMV 
Pelleted untreated neutrophils (UN), 50ng/ml TNFα-treated neutrophils (TN) and Ultra-
centrifuged NDMV (MV) resuspended in 49μl antibody binding buffer (10 mm Hepes, pH 
7.4, 140 mm NaCl, 2.5 mm CaCl2), before the addition of 1μl Annexin V-FITC, CD11b-
FITC, CD14-PE, CD16-PE and CD66-FITC at a 1:100 dilution. Negative control (NC) was 
set as non-stained neutrophils with fluorescent antibodies. After 10 min incubation in the 
dark at RT, cells and NDMV were diluted and resuspended in 50μl antibody binding buffer 
before analysis by flow cytometry using a CytoFlex and CytExpert software (Beckman 
Coulter, California, US). Before adding samples to process flow cytometry, 1μl microbeads 
with 1,000nm diameter (ThermoFisher, Massachusetts, US) to identify gating area of 
microvesicles which predicted size < 1,000nm. Figure 9 shows microbeads and NDMV 




Figure 9. Size reference by microbeads in flow cytometry.  Microbeads size was 1,000nm 
with green plot and gating square. NDMV diameter was less than 1,000nm and displayed 
with red scatter plots and gating area. NDMV gating area was used for further surface 
markers expression analysis. 
 
3.21 microRNA sequence 
3.21.1 microRNA extract  
The miRNeasy Mini Kit (Qiagen, Hilden, Germany) was used to isolate total RNA 
including microRNA and other small molecular weight small RNAs. TNF-
treated/untreated neutrophils and NDMV were pelleted and lysed in 700μl QIAzol reagent 
in RNase-free microcentrifuge tube. After the lysate was incubated at RT for 5min, 
chloroform (140μl) was added and mixed completely with lysate. The mixture was 
incubated at RT for 3min and then centrifuged at 12,000g for 15min at 4°C. The upper 
aqueous phase was removed into the collection tube and mixed with 100% ethanol of 525μl. 
The mixture with volume of 700μl was transferred into the mini spin column which was 
placed in the collection tube. After centrifuge at 10,000g for 15s at RT, the buffer RWT was 
filled into the mini spin column and centrifuged again. The mini spin column was washed 
twice by 500μl buffer RPE. The mini spin column bound with total RNA was moved into 
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new collection tube. The membrane of mini spin column was added with 30μl RNase-free 
water and placed at RT for 1min to improve RNA dissolution. The eluate was collected by 
centrifugation at 10,000g for 1min. The obtained 30μl eluate were transferred to the 
membrane and centrifuged twice. 
3.21.2 Agarose gel electrophoresis for RNA integrity 
The 1% solid agarose gel was placed in an electrophoresis gel box and covered with 1×TAE. 
The RNA sample of 1000ng was mixed with 6× loading buffer of 5μl and 100% formamide 
15μl. After loading RNA mixture into a relevant well of the agarose gel, the electrophoresis 
started at 80V for 30min. The whole agarose gel was stained by 0.5µg/mL EtBr solution 
for 15min, then washed gel 3 times by DEPC-treated water. RNA bands were visualized 
on the ultraviolet transilluminator-Gel Doc 1000 (Bio-Rad, CA, USA). 
3.21.3 Sequencing microRNA 
The microRNA sequence library was prepared on NEBNext® Poly(A) mRNA Magnetic 
Isolation Module (New England Biolabs), RiboZero Magnetic Gold Kit 
(Human/Mouse/Rat) (Epicentre, an Illumina Company) and NEB Multiplex Small RNA 
Library Prep Set for Illumina. TruSeq Rapid SR Cluster Kit (#GD-402-4001, Illumina) was 
used for microRNA sequence by Illumina NextSeq 500. This experiment was completed 
by Aksomics Technology Company (China). The raw sequencing data was accessed 
through quality control to decide what raw data should be used for further analysis. Data 
analysis progress was shown in Figure 10. 
         Quality control was processed on Solexa CHASTITY software to filter low quality 
reads and obtain clean reads. The cutadapt software was used to cut head of clean reads 
and keep tag with length equal and greater than 15nt, the collect trimmed reads for further 
analysis. The miRDeep2 software to quantify known microRNA and predict novel 
microRNA. The R software and its package edgeR was used to analyse different expression 
to find significant differences after clean reads were standardized by counts per million 
(CPM) with reference genome (GRCh38) (Figure 11).  
         Significantly different microRNA was conducted by 2-dimentional cluster analysis 
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and visualized with heatmaps. The different expression of microRNAs will be analysed by 
Ingenuity Pathway Analysis (IPA) (Qiagen, Redwood, US). The target genes of 
microRNAs were searched in three databases: TargetScan (Version 6.2) and miRDB 
(Version 4.0) and miRTarBase on the internet website miRWalk 2.0 
(http://mirwalk.umm.uni-heidelberg.de/) (Dweep and Gretz, 2015). These target genes 


















Part D: NDMV Effects on FLS Function 
3.22 MTT assay 
The metabolic activity of FLS co-cultured with or without NDMV was evaluated by the 3, 
(4, 5-dimethylthiazol-2-yl) 2, 5-diphenyl-tetrazolium bromide (MTT) assay. 3,000 FLS 
were seeded in a 96-well plate for 24h, and then PBS-washed wells were refilled with 60μl 
DMEM/10%FBS and conditioned media which contained DMEM/10% FBS and different 
vesicle/cell ratio: 10:1, 20:1, 30:1, 50:1, 100:1, 200:1, 300:1, 400:1 or 10 ng/ml TNF-α 
prior to co-culture for 24h. Media was then removed, then PBS washed 3 times. 
Subsequently, 100μl culture media with 0.5mg/ml MTT was added in each well and 
incubated for 4h at 37°C. MTT was removed and replaced with 100μl DMSO to dilute 
formazan crystals by shaking horizontally for 10min and incubated at 37°C for 30min. The 
absorbance of dissolved purple crystals in a 96-well plate were measured at 570nm by a 
microplate reader- Multiskan GO (Thermo Fisher, MA, US). DMSO-diluted FLS without 
MTT incubation was used as the blanks. The viability of FLS in the control group without 
NDMV co-culture was set as 100%, which was a relative value to other groups. Each 
conditioned treatment was repeated 5 times. 
 
3.23 Scratch wound healing assay 
105 of log phase FLS (Passage 4) were incubated in 6-well tissue culture plates and 
incubated for 24h to form a monolayer. A 200 µL pipette tip was used to scratch a line and 
remove cells. Each well was washed twice with 1mL DMEM/10%FBS to remove floating 
cells. Two mL of DMEM/10%FBS (± NDMV) were added to each well and the plate was 
incubated for 24h and 48h. Cells were washed twice with PBS and fixed with 300µl 4% 
PFA for 15min. The cells were then stained with 300µl 0.1% crystal violet for 30min and 
washed with PBS for 10 times. Images of monolayer cells were captured by microscopy:  
EVOS M5000 Imaging System (ThermoFisher Scientific, Massachusetts, US). The area of 
cells between the original scratch lines was evaluated by ImageJ software and % regrowth 
area was calculated to represent cell proliferation ±NDMV treatments. The percentage of 
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scratch wound regrowth area was set as a baseline 0% after scratching at 0h. 
 
3.24 NDMV labeled by fluorescent PKH26 
To quantify the amounts of NDMV taken up by FLS, the phospholipid bilayer membrane 
of microvesicles was stained by PKH26 Red Fluorescent Cell Linker Kits for General Cell 
Membrane Labelling (Sigma-Aldrich, St. Louis, US). MV pellets obtained after ultra-
centrifugation were resuspended gently in 100μl Diluent C. Equivalent 2× Dye Solution 
(PKH26 solution : Diluent C = 4μl : 1000μl) was added with the NDMV mixture and 
incubated for 5min at room temperature (RT). 200μl EV-free serum was used to pause 
staining for 1min at RT to stop staining. Additional 5ml RPMI 1640/5% EVs-free serum 
was supplied to wash the PKH26 dyed NDMV and dilute or combine leftover unbound 
PKH26. Next, the ultra-centrifugation was used to re-pellet PKH26-stained NDMV at 
100,000g for 30 min at 4°C which was diluted in 100μl RPMI 1640 and co-cultured 
immediately with P4 or P5 FLS to measure microvesicles internalization by flow cytometry 
and confocal microscopy.  
 
3.25 NDMV uptake by flow cytometry 
2×104 FLS of logarithmic growth phase (Log GP) in P4 were seeded in each well of a 24-
well plate and cultured for 24h. Adhered cells were co-cultured with 400μl 
DMEM/10%FBS and conditioned media and incubated with NDMV (labelled with PKH26) 
for various time points from 0.5 to 24h. Cells were harvested with 0.25% trypsin and fixed 
in 4% PFA for 15min at RT. After centrifugation at 900g for 3min at RT, cells were 
resuspended in 500µl PBS and NDMV uptake was measured by flow cytometry using the 
LSR II (BD Biosciences, Bedford, US) which was fitted with a 50mW of 488nm blue laser. 
Forward and side scatter were adjusted to capture an FLS within the gating area. The 
signals of PKH26 red fluorescence were captured on the PE channel (564-606nm) and 
analysed by FCS Express 4 Reader (De Novo Software, Glendale, US) and R package 




3.26 NDMV uptake by confocal microscopy 
Before seeding 2×104 FLS in logarithmic growth phase of P4 for 24h, tissue-culture treated 
glass coverslips (WHB Scientific, Shanghai, China) were placed in a 24-well plate. 400μl 
conditioned media containing labelled NDMV were added for the indicated times, then the 
plate was washed with DMEM/10%FBS once. Co-cultured cells were fixed with 4% PFA 
for 15min at RT and washed with PBS twice. 0.5% Triton X-100 (Thermo Fisher, MA, US) 
was used to permeabilize cells for 10min at RT and then washed in PBS twice. Non-specific 
binding was blocked with 5% FBS for 30min. Flash Phalloidin Green 488 (Millipore, 
Billerica, US) at a ratio of 1:100 in PBS was used to stain cellular F-actin for 20min. 300nM 
DAPI solution (Millipore, Billerica, US) in PBS was used to stain cell nuclei for 5 min. 
Eventually, coverslips were rinsed with deionized water 3 times and transferred to mount 
slides with an antifade solution (Millipore, Billerica, US). Slides were viewed on a confocal 
microscope to capture images: FluoView FV10i (Olympus, Tokyo, Japan) and LSM800 
(Zeiss, Oberkochen, Germany).   
 
3.27 Inflammatory cytokines levels by multiplex assay 
2ml DMEM/10%FBS was used to culture 105 FLS in logarithmic growth phase of P4 for 
24h and washed in PBS twice. Adhered cells were co-cultured with DMEM/10%FBS or 
conditioned medium at the appropriate vesicle/cell ratio and indicated times. Co-cultured 
media was collected and ultra-centrifugated at 200,000 x g for 60 min at 4°C to remove 
NDMV and EV for further assay. Cytokines levels in co-cultured media were measured by 
a commercial kit: Bio-Plex Pro Human Cytokine 17-plex Assay (Biorad, Hercules, US). 
All processes of testing adhered strictly to the protocol and quick guide from Bio-Plex Pro 
Assay for Human Cytokines Assay. 50μl diluted magnetic beads was added to an assay 
plate which was washed twice with Wash Buffer. Co-cultured media 50μl was added to 
each well and incubate with the beads for 30min at RT with shaking. After washing the 
plate, 25μl detection antibody was added and incubated for 30min at RT with shaking. The 
plate was washed 3 times again, and 50μl diluted Streptavidin-Phycoerythrin (SA-PE) 
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added and incubated for 10min.  Lastly, 125μl assay buffer was added to resuspend 
magnetic beads and shaken for 30s. The assay plate was moved to Bio-Plex 200 Systems 
(Biorad, Hercules, US) to measure cytokines concentrations. Cytokines detection range 
illustrated in Table 8. 
 
Table 8. The detectable ranges of 17 human cytokines levels in Bio-Plex Pro Human 
Cytokine 17-plex Assay. 
cytokine 
detection range (pg/ml) 
lower upper 
IL-1β 3.2 3,261 
IL-2 2.1 17,772 
IL-4 2.2 3,467 
IL-5 3.1 7,380 
IL-6 2.3 18,880 
IL-7 3.1 6,001 
IL-8 1.9 26,403 
IL-10 2.2 8,840 
IL-12 p70 3.3 13,099 
IL-13 3.7 3,137 
IL-17 4.9 12,235 
G-CSF 2.4 11,565 
GM-CSF 63.3 6,039 
IFN-γ 92.6 52,719 
MCP-1 2.1 1,820 
MIP-1β 2 1,726 






Chapter 4. RESULTS 
Part A: FLS Culture and Properties 
4.1 Contamination detection 
Bacterial, fungal and yeast contamination of cell cultures can be visualized by light 
microscopy and Figure 12A shows black rods that were observed in some FLS cultures 
which resulted from probable bacterial contamination. Figure 12B shows examples of 
filaments in cell culture media caused from probable mould contamination. Any 
contaminated cultures were discarded from our experiments and possible contaminated 
culture media solutions were discarded. Incubators, biosafety cabinet and others associated 
equipment were routinely cleaned and sterilized. 
         Mycoplasma contamination is not detectable by microscopic observation during the 
cell culture and so a PCR-based method was used to detect mycoplasma contamination. 
Agarose-gel electrophoresis showed that a PCR product for the positive control (P) was 
located between 250-300bp shown in Figure 12C. The negative control (N) did not show 
any PCR products within the 250-300bp this size range. All samples were found not to 









Figure 12. Culture contamination detection. (A) Suspected bacterial contamination was 
identified under light microscopy. Black rods and dots were sometimes found (white 
arrows). (B) Fungal contamination could be identified under microscopy. Black filaments 
were sometimes detected in culture media (white arrow). (C) Mycoplasma contamination 






4.2 Cell growth curve 
Primary culture is a fundamental approach to obtain cells from tissues, which included two 
classical methods: explant/tissue block culture and dispersed/ enzymatic culture. In explant 
culture, single cells secede radially from tissue, which defined as tissue culture or passage 
0.  In dispersed culture, tissue was dissociated into single cells by enzymes, which were 
then seeded into flasks (75cm plastic flask) as passage 0. After single cells proliferated to 
85%, cells were sub-cultured into passage 1 until passage 4 for using. During 8-days of 
culture, 3 phases of growth kinetics were detected: lag phage, exponential phase and the 
beginning of stationary phase (Figure 13). The growth curve of dispersed cells in culture 
(passage 1) showed an initial decline below 10,000 cells/ml on days 1, 2 and 3, but this 
initial decline was not detected in passage 4 cultures, where cell concentrations were above 
10,000 cells/ml on days 1, 2 and 3 (Figure 13A). Before day 5, the cell density of passage 
1 was lower than that of passage 4 in dispersed cell cultures. Nevertheless, the cell density 
of passage 1 was higher than that of passage 4 on days 6, 7 and 8. The differences in FLS 
densities were significant between passage 1 and passage 4 in dispersed cell cultures on 
day 8 (p < 0.0079). No significant differences were found between passage 1 and 4 on other 
days.  
         The growth curve of explant cultures in passage 1 showed an initial decline below 
10,000 cells/ml on days 1, 2 and 3 also, but the initial decline did not appear in passage 4, 
whose cell concentrations were above 10,000 cells/ml on day 1, 2 and 3 (Figure 13B). 
Before day 4, the cell density of passage 1 was lower than that of passage 4 by explant 
culture. Nevertheless, the cell density of passage 1 was higher than that of passage 4 on 
days 5, 6, 7 and 8. The differences in cell densities were significant between passage 1 and 
passage 4 by explant culture on day 8 (p < 0.0159). There was no significant difference 









Figure 13. FLS growth curve in passage 1 and 4 by primary culture. (A) The cell growth 
curve of FLS by dispersed cell culture. On day 8, the cellular density of passage 1 was 
higher than that of passage 4. (B) The cell growth curve of FLS by explant culture. On day 
8, the cellular density of passage 1 was higher than that of passage 4. Values shown are 




4.3 Cell doubling time 
Figure 4.3 shows the doubling time of these dispersed cell cultures which was 62.20 ± 0.45 
h (mean ± SE) in passage 1, which was lower than 71.41 ± 1.36 h in passage 4, a difference 
that was statistically-significant (p < 0.0079). The mean cell doubling time in passage 1 
was 63.63 ± 1.41h, which was lower than 76.19 ± 4.49h in passage 4 (p < 0.0159). However, 
the population doubling time in passage 1 was not significantly different between dispersed 
cell cultures and explant cultures (p = 0.5476). When compared to passage 4 of explant 
cultures, the population doubling time of passage 4 of dispersed cell cultures was not 
significantly different (p = 0.6905). 
 
Figure 14. The cell doubling time of passage 1 cultures and passage 4 cultures: dispersed 
cell cultures and explant cultures. Values shown are mean (±SE), N=5 separate 





4.4 Culture duration time  
Two different methods were used to isolate FLS. The first was to use explant cultures, 
allowing the FLS to naturally grow out from the synovium sections. The second was to 
enzymatically disperse cells by treatment with collagenase and trypsin. 85% confluency 
of FLS was set as the cell density prior to subculture. The culture duration times were 
recorded in different passages of dispersed cell cultures and explant cultures (Figure 15). 
Compared to passage 0, cells in dispersed cell cultures took 4.0 d (±0.9) to reach this 
level of confluency, while cells in passage 0 of explant cultures took longer to achieve 
85% confluency (14.0 ± 1.1 d), a statistically-significant difference (p = 0.0117).  For 
passages 1, 2, 3 and 4, the mean times to achieve 85% cellular confluency by explant 
cultures were longer than those for dispersed cell cultures, but significant differences 
were not found. Based on different culture duration time of two methods, dispersed cell 







Figure 15. Cell culture time. The culture time in passage 0 of explant cultures to achieve 
85% confluency was greater than that of dispersed cells. The time (in days) for explant 
cultures to achieve 85% confluency was 7.0±1.2, 7.2±0.4, 7.4±1.5 and 7.6±1.1 d, for P1 to 
P4, respectively, while dispersed cell cultures this time was 6.6±1.1, 7.0±1.3, 7.2±0.8, 
7.4±1.1 d. Values shown are mean (±SE), N=5 separate experiments, data analyzed by the 











4.5 Cell cycle kinetics of P1 and P4 of dispersed cells 
The cell cycle kinetics can be influenced by different passage stages or FLS purity, and 
flow cytometry was used to test cell phases of P1 and P4 cultures.  In Figure 16A and B, 
two peaks are apparent, representing G0/G1 (Gap 0 and 1) phases and G2/M (Gap 2 and 
mitosis) phases, respectively. The trough between peaks represents the cells in S phase 
(DNA Synthesis). 69.23±0.49% cells of P1 were in G0/G1 phase (Figure 16A), while 
73.42±1.05% cells of P4 were in G0/G1 phase (Figure 16B) (p = 0.0362). 14.56±0.36% of 
P1 cultures were in S phase, which was greater than cells ion P4 (11.43±0.71%) and this 
difference between P1 and P4 was statistically significant (p = 0.0159). The percentage of 
P1 cells in G2/M phase was 16.20±0.32% which was not different from that of P4 cultures 

















Figure 16.  Cell cycle distribution analysis 
of P1 and P4 cultures. (A) The cell phases 
were determined by DNA content of P1 
cells while in (B), P4 cells were analysed. 
(C) Percentages of P1 and P4 cells in 
different phases were analyzed. The 
percentage of P1 cells in G0/G1 was 
significantly lower than that of P4 cells, 
but the percentage of P1 cells in S phase 
was significantly higher than that of P4 
cells. There was no significant difference 
in the G2/M phase between the different 
cultures (N=5). Values shown are mean (± 










4.6.  Passage 4 FLS purity increase by dispersed cell culture increase 
FLS purity was confirmed by staining cultured cells with fibroblast-positive and -negative 
antibodies: CD90+, CD55+, CD11b- and CD64- was used to confirm the identity of FLS 
by flow cytometry. Figure 17 and show an example of the expression of these four CD 
markers on cultured cells from P1 and P4 from a single patient sample, with the marker set 
as 0% positive for unstained cells.  74.2% of the cells in P1 were CD90+ and this was 
increased to 98.9% for P4 cells (Figure 17A). 45.7% of cells were CD55+ in P4 which was 
increased compared to P1 cells (Figure 17C). The two macrophage markers CD11b and 
CD64 were decreased from 34.9% to 1.6% and from 19.0% to 5.8%, respectively as culture 
passage number increased from P1 to P4 (Figure 18A and C).  
         Five separate knee OA patient samples were cultured and expression of these CD 
markers determined: results are shown in in Figure 17 and 18. Figure 17B shows that 
99.2±0.06% of the cells in P4 were CD90+, which was significantly higher than that of P1 
cells (73.5±0.8%, p = 0.0079).  Figure 17D shows that 35.6±0.50% of the cells in P1 were 
CD55+, but this was significantly increased to 90.0±2.3% in P4 cells. CD11b+ and CD64+ 
positive cells decreased from 36.3±0.8% and 23.0±2.8%, respectively in P1, to 1.8±0.4% 
and 4.6±0.6%, respectively, in P4 (p < 0.01) (Figure 18B and D).  
         In Figure 4.8, the values of CD90 MFI (on a logarithmic scale) in P1 and P4 were 
3.0013±0.0101 and 3.8205±0.0100 which were significantly higher than 1.9387±0.0170 in 
the negative controls (p=0.0002, p<0.0001, respectively).  Furthermore, the MFI of CD90 
in P4 was significantly greater than that in P1 (p=0.0002). The MFI values of CD55 
(logarithmic scale) were 2.3601±0.0172, 3.0312±0.0158 and 3.8290±0.0124 in negative 
control, P1 and P4 (p<0.001), respectively). The MFI of CD11b was significantly higher 
in P1 (2.881±0.0173) than in the negative control (2.121±0.0149) and P4 (2.174±0.0369) 
(p=0.0002 and p=0.0010, respectively). There was no significant difference in MFI for 
CD11b between the negative controls and P4 cells (p = 0.1522). Similarly, there was no 
significant difference in CD64 expression between negative controls (2.5010±0.0071) and 
P1 cells (2.6009±0.0318, p=0.0900).  However, the MFI of CD64 of P1 cells was higher 








Figure 17. FLS purity of P1 and P4 determined by expression of fibroblast markers. (A) 
and (C) shows the percentage of CD90+ and CD55+ cells in negative control (Red traces 
and bars), P1 (green traces and bars) and P4 (blue traces and bars) from a single patient 
sample. (B) The mean percentage of CD90+ and CD55+ cells in negative control, P1 and 
P4 from N=5 separate experiments. The percent of CD90+ and CD55+ cells in P1 was 
significantly lower than in P4. Values shown are mean (± SE). Data analyzed with 










Figure 18. FLS purity of P1 and P4 determined by expression of macrophage markers (A) 
and (C) shows the percentage of CD11b+ and CD64+ cells in negative controls (Red traces 
and bars), P1 (green traces and bars) and P4 (blue traces and bars) from a single patient 
sample. (B) The mean percentage of CD11b+ and CD64+ cells in negative controls, P1 
and P4 from N=5 separate experiments. The percent of CD11b+ and CD64+ cells in P1 
was significantly higher than in P4. Values shown are mean (± SE). Data analyzed with 





Figure 19. MFI values (logarithmic scale) of positive and negative fibroblast CDs markers. 
The logarithm values of CD90+ and CD55+ cells in P4 were higher than in the negative 
controls and P1. The values of CD11b+ and CD64+ cells in P4 were higher than in negative 






Part B: Neutrophil Isolation and Functional Assays 
4.7 Neutrophil purity by microscopy 
Isolated cells on cytospins were stained with Wright’s stain to identify the level of purity 
and types of contaminating cells. In Figure 20, all cell nuclei were stained blue and 
typically, the neutrophil nucleus contained 2-5 lobes while the cytoplasm stained pink. 
Eosinophils were identified as their cytoplasm stained bright red while basophil cytoplasm 
(very rarely detected) was dark blue by Wright’s staining. The nucleus of lymphocytes was 
distinct from that of granulocytes and was round and stained dark blue (Figure 20A). The 
purity of neutrophils isolated by Polymorphprep by this visual determination was 
98.15±0.05% while contaminating cells comprised: eosinophils 0.84±0.07%; basophils, 
0.19±0.05%; mononuclear phagocytes 0.36±0.06% and lymphocytes 0.46±0.05 (Figure 
20B).   
 
4.8 Neutrophils purity by flow cytometry 
The purity of isolated neutrophils was also measured by flow cytometry. Firstly, single 
cells (singlets) were gated to separate doublets of cells (Figure 21A). Neutrophils in the 
gated singlets were identified by their characteristic FSC-H and SSC-H properties. By this 
method, neutrophil purity was calculated as 98.25% and monocytes percentages were 1.75% 
(result from a single experiment, Figure 21B). In 5 separate experiments, neutrophil 
percentage was calculated as 98.50±0.19% and monocyte percentage contamination was 










Figure 20. Image of isolated neutrophils stained by Wright’s solution and visualized by 
light microscopy. (A) Neutrophils’ nuclei stained by methylene blue was identified as 2-5 
lobes and their cytoplasm contained granules stained pink by eosin red. The eosinophil 
cytoplasm is bright red and again, the nuclei are identified as 2-5 lobes. 100× (B) The purity 
of 5 separate preparations of neutrophils isolated by Polymorphprep was approximately 






Figure 21. Flow cytometry analysis of 
neutrophil purity. (A) separation of singlets 
and doublets in a FSC-A and FSC-H plot. 
(B) scatter plot of neutrophils by FSC-H 
and SSC-H channel in a single experiment. 
(C) Summary of neutrophil and monocyte 










4.9 Inhibition of chemotactic migration of neutrophils treated with TNFα 
The effects of various treatments on human neutrophil migration was examined utilizing a 
modified transwell assay containing upper and lower chambers. In these experiments, 
neutrophils migrated into the lower chamber under the influence of neutrophil chemotactic 
factor, fMLP (10-8mol/L) placed in the lower chamber. The neutrophils from sepsis patients 
were used as a positive control as these have decreased migration (Zonneveld et al., 2016). 
5×106 neutrophils were added into the upper chamber and after incubation for 90min at 
37°C, neutrophils that had migrated into the lower chamber were counted by a 
hemocytometer. Cell migration (%) was calculated as the number of neutrophils in lower 
chamber divided by total neutrophils number added in the upper chamber. Compared to 
the percentage migration of untreated neutrophils (88.2±1.3%), the TNFα (50ng/ml) 
treated neutrophil migration was decreased to 76.2±2.2% (p = 0.0001). As a positive 
control, the migration of neutrophils from sepsis patients was 49.60±2.09%, which was 







Figure 22. Effects of TNFα on fMLP-induced neutrophil chemotaxis measured in a 
transwell assay. Cells were incubated in the absence (-) or presence (+) of 50ng/ml-TNFα-
treated: sepsis neutrophils were not treated with TNFα. 5×106 cells were added into the 
upper chamber and incubated for 90min at 37°C. FMLP 10-8mol/L was the chemotactic 
factor in lower chamber. The migration percentages were 88.2%, 76.2% and 49.6 in 
untreated neutrophils, TNFα-treated neutrophils and sepsis neutrophils, respectively. Cell 
migration (%) was calculated as the number of neutrophils in lower chamber divided by 
total neutrophils number added in upper chamber. The data were mean ± S.E. of five 




4.10 CD11b and CD62L expression on the surface of TNFα-treated and untreated 
neutrophils 
We then measured the effects of TNFα, at the concentration used to produce microvesicles 
(50ng/mL) on CD11b and CD62L expression of neutrophils. Neutrophils were therefore 
incubated for 20 min in the absence (control) and presence of 50ng/mL TNFα at 37°C. 
Previous work has shown that TNFα can up-regulate and down-regulate, respectively, 
levels of these receptors (Headland et al., 2015). The expression of CD11b and CD62L on 
freshly-isolated neutrophils and TNFα treated neutrophils are shown in Figure 23. In 
untreated, control neutrophils, 74.8% of the neutrophil population was CD11b+, while in 
TNFα treated neutrophils 86.1% of the cells were CD11b+ (Figure 23A). The MFI of 
CD11b in TNFα treated neutrophils was raised to 13580.54±1.02 MFI, compared to 
7146.74±1.01 MFI untreated neutrophils (p = 0.0079) (Figure 23B).  In comparison, 99.5% 
of control neutrophils were CD62L+ neutrophils while in TNFα-treated neutrophils <1% 
of the cells were CD11b+ (Figure 23C). The MFI of CD62L in untreated neutrophils was 
114698.80±1.01 MFI, while this decreased to an MFI of 55.90±1.01 in TNFα-treated 










Figure 23. CD11b and CD62L surface expression on neutrophils by direct flow cytometry. 
(A) and (B) CD11b expression on neutrophils ± 50ng/mL TNFα for 20min. (C) and (D) 
CD62L expression on neutrophils with/out treatment of TNFα, as above. The data are 




4.11 Respiratory burst activity of TNFα treated neutrophils 
TNFα directly stimulated luminol-amplified chemiluminescence (CL) of human 
neutrophils, but the response was low compared to levels of CL stimulated by fMLP and 
PMA. For TNFα treatment, chemiluminescence values were between 5000 to 15000 AU 
(arbitrary units) and this increased slowly over a 30min period (Figure 24A). However, 
neutrophils pre-incubated with high-dose TNFα (50 ng/mL) displayed marked 
enhancement of chemiluminescence after stimulation with fMLP and PMA. However, the 
maximal responses and time to peak response were different between fMLP and PMA 
stimulation. The peak of CL was highest (32329 AU) at 40s after fMLP stimulation, while 
after 4min, the CL curve of TNFα primed/ fMLP stimulated cells overlapped with that of 
TNFα priming. CL responses after 30min were not significantly different (p=0.1925, 
Figure 24B). The peak of CL was highest (65695 AU) 200s after PMA stimulation, the 
peak value of which was increased 2-fold compared to fMLP stimulation. The total CL 
over 30min was significantly different between neutrophils activated with TNFα alone and 
neutrophils pre-incubated with TNFα and stimulated with PMA (p<0.0001). In comparison 
to the CL response of TNFα activation alone and TNF followed by fMLP, the CL average 







Figure 24. Effect of TNFα on neutrophil luminol-amplified chemiluminescence stimulated 
by fMLP and PMA. (A) Representative time-dependent curves with TNFα only and TNFα 
pre-treatment followed by fMLP and PMA stimulation. (B) summary data of total CL 












4.12 Apoptosis of untreated and TNFα treated neutrophils 
To measure the effects of TNFα (at the concentration and incubation time used to make 
microvesicles) on neutrophil death, an Annexin V and Propidium Iodide (PI) apoptosis 
assay was conducted. Freshly-isolated neutrophils were incubated without (control) and 
with 50ng/ml TNFα for 20min at 37°C after which time neutrophils were stained with 
Annexin-V FITC and PI prior to flow cytometry. Apoptosis levels of freshly-isolated 
neutrophils were comparable to those of untreated controls (Figure 25A and B). The 
numbers of viable (non-apoptotic) neutrophils were not significantly different between 
untreated neutrophils and TNF-treated cells (98.01±0.28% v.s. 97.80±0.22%, respectively, 
p=0.0952) (Figure 25C). The numbers of early apoptotic and late apoptotic/necrotic 
neutrophils were also not significantly different between samples (p=0.1508 and p=0.3095 
respectively). The percentage of early apoptotic cells was 0.79 ±0.03% in untreated 
neutrophils and 0.86 ±0.03% in TNF-treated neutrophils (Figure 25D), while the 
percentage of late apoptotic/necrotic cells was 1.20 ±0.26% in untreated neutrophils and 
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Figure 25. Annexin–V FITC/PI assay to measure neutrophil apoptosis. (A) Neutrophils 
were incubated in the absence (-TNFα, A) or presence (-TNFα, B) of 50 ng/mL of TNFα 
for 20 min. Early apoptotic cells (annexin V positive, PI negative) are seen in the lower 
right quadrant while late apoptotic/necrotic cells (annexin-positive and PI-positive) are 
seen in the upper right quadrant.  Cells in the lower left quadrant are viable (non-apoptotic) 
cells, with dead cells in the upper left.  In (C)-(E) neutrophils were incubated in the absence 
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or presence of TNFα showing viable (non-apoptotic cells) in (C), early apoptotic cells 
(annexin-positive and PI-negative) and in (D) and late/necrotic cells (annexin-positive and 





Part C: NDMV Isolation, Purification and Properties 
4.13 Morphological and size characteristics of NDMV measured by TEM and SEM 
Electron microscopy is often used to confirm the identity of EVs, and their size is 
characteristic of the type of EVs. TEM showed that the NDMV prepared and isolated in 
this study resembled a cup (minus a handle) and their size ranged from 200 to 500nm in 
diameter (Figure 26A).  When visualised by SEM, NDMV had an irregular spherical 
appearance, with an uneven surface, and their size again mainly ranged from 200 to 500nm 
in diameter (Figure 26B), but some vesicles were smaller than 100nm. NDMV diameter 
was measured by Image J software. The average of minimum diameter from SEM and 
TEM is shown in Figure 26C-E. The minimum diameter measured by SEM (111.03 
±6.04nm) was lower than that measured by TEM (203.23±14.63nm), and this difference 
was statistically significant (p<0.0001) (Figure 26C). The maximum diameter measured by 
SEM (138.26±7.61nm) was lower than that measured by TEM (260.95±19.52nm), and 
again, this difference was significant (p<0.0001) (Figure 26D). The average diameter 
measured by TEM’s (204.20±9.16nm) was significantly greater than that measured by 
SEM (124.64±6.54nm) (p<0.0001) (Figure 26E). These significant differences in NDMV 
diameter measured by these two techniques could be due to the various processing steps of 
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Figure 26. Images of NDMV by SEM and TEM. (A) TEM image of NDMV. (B) SEM 
image of NDMV. (C-E) show minimum, maximum and average diameter of NDMV, 
respectively, determined by Image J. The data shown are mean ± S.E. of five separate 




4.14 Nanoparticle tracking assay (NTA) to characterize NDMV 
NDMV were also characterised by Nanoparticle Tracking Analysis (NTA). As the NDMV 
pass through a laser beam, light was scattered and the Brownian motion of the particles can 
be recorded using this technique (Figure 27A). Figure 27B-E shows NTA report of NDMV 
concentration and size. By this methodology, the diameter of the NDMV ranged from 
38.41 to 1000.00nm, with a mean value 232.3 ± 8.9nm. NDMV with a diameter of <100nm 
comprised approximately to 2-3% of the total population. The NDMV concentration was 
calculated as 3.8×108 ± 1.9×107 particles/mL by this method. This analysis revealed that 
MV were present as 4 discrete sub-populations, based on their size (Figure 27F) with the 












Figure 27. NTA of isolated NDMV from TNFα treated neutrophils. (A) Superimposed 
images captured by NTA demonstrating Brownian motion of highlighted white particles. 
(B) Dissimilar colours and areas of squares represent NDMV scattered light intensity and 
size from the 5 individual videos/measurement of each sample. (C) The graph shows the 
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distribution of NDMV size versus their concentration (107 particles/ml). Each curve with 
distinct colour represents measurements from different samples. (D) Nanosight NTA 
software calculated average of NDMV size and concentration automatically by finite track 
length adjustment (FTLA) and plotted their relationship by 5 individual videos of one 
sample. The black line represents NDMV distribution of size and concentration average 
from 5 videos of one NDMV sample. The red trace shows the standard error of the means. 
(E) Text report displayed statistical description from 5 videos of one NDMV sample. D10 
was used to represent intercepts for 10% of cumulative metrics, D50 for 50% and D90 for 
90%. (F) Size distribution against concentration of NDMV was plotted from 5 independent 
samples were measured by NTA for 5 videos of each sample. The blue curve represents 
the mean concentrations of differently-sized NDMV while the pink trace shows standard 







4.15 Annexin V expression on the surface of NDMV 
To confirm annexin V expression on the surface of neutrophils surface, flow cytometry 
was utilized to measure mean fluorescent intensity (MFI) on untreated neutrophils (UN), 
TNFα treated neutrophils (TN) and NDMV. Negative control (NC) was set as non-stained 
neutrophils. Figure 28A shows histograms of FITC-anti annexin V labeled cells and 
microvesicles. No significant differences were detected in the surface expression of 
annexin V on NC and UN (p=0.1979) or NC and TN (p=0.1182) (Figure 28B). The MFI 
of annexin V on UN and TN were not significantly different, which is consistent with 
previous results in Figure 25. However, annexin V expression on the surface of NDMV 






Figure 28. FITC-Annexin V expression on the surface of neutrophils and NDMV. (A) 
Histogram of log10 (FITC-A) annexin V of untreated neutrophils (UN), TNFα treated 
neutrophils (TN) and NDMV. NC was negative control of neutrophils in the absence of 
annexin V. (B) Annexin V MFI on the surface of UN, TN and NDMV showing mean±S.E. 
of five separate experiments.  Tukey multiple comparisons of means was used for statistical 





4.16 CD11b expression on the surface of NDMV 
After 50ng/ml TNFα treatment for 20min, CD11b expression increased on the surface 
membrane of neutrophils. Flow cytometry was then used to measure CD11b expression on 
the surface of intact neutrophils and NDMV. Mean fluorescent intensity (MFI) was 
measured on untreated, control neutrophils (UN), TNFα treated neutrophils (TN) and 
NDMV. Negative control (NC) was set as non-stained neutrophils. Figure 29A shows 
histogram of FITC-anti CD11b labeled cells and microvesicles, indicating that expression 
of this receptor increased following TNF treatment, but this receptor was only present at 
low levels on the surface of NDMV. Figure 29B shows that CD11b expression on TN was 
significantly increased compared to UN (p<0.0001), which was consistent with previous 
results (Figure 23). CD11b expression on the surface of UN, TN and NDMV were 
significantly higher than NC (p<0.0001, respectively). The CD11b MFI on NDMV was 
significantly lower than on both UN and TN (p<0.0001). 
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Figure 29. FITC-CD11b expression on the surface of neutrophils and NDMV. (A) 
Histogram of log10(FITC-A) CD11b of untreated, control neutrophils (UN), TNFα treated 
neutrophils (TN) and NDMV. NC was negative control of neutrophils without fluorescent 
antibody staining. (B) CD11b MFI on the surface of NC, UN, TN and NDMV showing 
mean ± S.E. of five separate experiments.  Tukey multiple comparisons of means was used 




4.17 CD14 expression on NDMV surface 
After 50ng/ml TNFα treatment for 20min, CD14 expression decreased on the surface 
membrane of neutrophils. Flow cytometry was then used to measure CD14 expression on 
the surface of intact neutrophils and NDMV. Mean fluorescent intensity (MFI) was 
measured on untreated, control neutrophils (UN), TNFα treated neutrophils (TN) and 
NDMV. Negative control (NC) was set as non-stained neutrophils with CD14. Figure 30A 
shows histograms of PE-anti CD14 labeled cells and NDMV. Figure 30B shows that the 
MFI of CD14 expression on UN and TN were significantly higher than NC (p<0.0001), 
while CD14 expression on UN was significantly higher than on TN (p<0.0001). Both UN 
and TN surface expression of CD14 were significantly greater than on NDMV’s. Although 
CD14 MFI on NDMV was higher than NC, there was no significant difference between 
expression levels (p=0.2043). 
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Figure 30. PE-CD14 expression on the surface of neutrophils and NDMV. (A) Histograms 
of log10 (PE-A) CD14 of control, untreated neutrophils (UN), TNFα treated neutrophils 
(TN) and NDMV. NC was negative control of neutrophils without fluorescent antibody 
staining. (B) CD14 MFI on the surface of UN, TN and NDMV shown as mean ± S.E. of 
five separate experiments.  Tukey multiple comparisons of means was used for statistical 




4.18 CD63 expression on NDMV surface 
CD63 expression was then measured on the surface of neutrophils ± treatment with 
50ng/ml TNFα for 20min, and on the surface of NDMV by flow cytometry.  Negative 
control (NC) was set as non-stained neutrophils with CD63. Mean fluorescent intensity 
(MFI) was measured on untreated, control neutrophils (UN), TNFα treated neutrophils (TN) 
and NDMV. Figure 31A shows histograms of PE-anti CD63 labeled cells and NDMV. 
There were no significant differences in CD63 MFI between NC and UN (p=0.9898) or 
between NC and TN (Figure 31B, p=0.9789).  CD63 expression on UN and TN was also 
not significantly different (p=0.9998). However, CD63 expression on the surface of 
NDMV was higher than on NC and UN (p=0.0190, p=0.0455, respectively). No significant 
differences were found between CD63 expression on TN and NDMV (p=0.0575). 
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Figure 31. PE-CD63 expression on the surface of neutrophils and NDMV. (A) Histograms 
of log10 (PE-A) CD63 of control, untreated neutrophils (UN), TNFα treated neutrophils 
(TN) and NDMV. NC was negative control of neutrophils without fluorescent antibody 
staining. (B) CD63 MFI on the surface of UN, TN and NDMV expressed as mean ± S.E. 
of five separate experiments.  Tukey multiple comparisons of means was used for statistical 




4.19 CD66 expression on NDMV surface 
CD66 expression was then measured on the surface of neutrophils ± treatment with 
50ng/ml TNFα for 20min, and on the surface of NDMV by flow cytometry.  Negative 
control (NC) was set as non-stained neutrophils with CD66. Mean fluorescent intensity 
(MFI) was measured on untreated, control neutrophils (UN), TNFα treated neutrophils (TN) 
and NDMV. Figure 32A shows histograms of FITC-anti CD66 labeled cells and MV and 
Figure 32B demonstrates that the MFI of CD66 expression on UN and TN were 
significantly higher than on NC (p<0.0001), while CD66 expression on UNs was 
significantly lower than TN’s (p<0.0001). Both UN and TN surface expression of CD66 
were significantly higher than on NDMV (p<0.0001, respectively). There was no 




Figure 32. FITC-CD66 expression on the surface of neutrophils and NDMV. (A) 
Histograms of log10 (FITC-A) CD66 of TNFα untreated neutrophils (UN), TNFα treated 
neutrophils (TN) and NDMV. NC was negative control of neutrophils without fluorescent 
antibody staining. (B) CD66 MFI on the surface of UN, TN and NDMV with data shown 
mean ± S.E. of five separate experiments.  Tukey multiple comparisons of means was used 




4.20 RNA isolation and characterisation from NDMV and neutrophils 
Before conducting microRNA sequencing, extracted total RNA (including microRNA) 
quality and concentration was assayed by Nanodrop 2000/2000c Spectrophotometers 
(ThermoFisher, Massachusetts, US). Total RNA samples extracted from untreated 
neutrophils (N), TNFα treated neutrophils (T) and neutrophil-derived microvesicles (M) 
from three separate volunteers (given notations of 9, 10 and 11).  Whole blood (50ml) was 
divided into two applications: 10ml for untreated neutrophils (N), 40ml for TNFα-treated 
neutrophils (T) and NDMV (M) generation. For spectrophotometry, the optical density 
(OD) 260/280 ratio should be close to 2.0 for pure RNA. The OD 260/280 ratio of cellular 
RNA were acceptable between 1.83 to 1.99, as well as an RNA concentration over 50ng/μl 
(Table 9).  
Table 9. Total RNA concentration from neutrophils and NDMV and their 260/280 ratio. 
Sample No. Concentration (ng/μl) OD 260/280 
N9 67.6 1.83 
N10 64.7 1.86 
N11 65.4 1.91 
T9 211.8 1.89 
T10 289.3 1.99 
T11 265.1 1.94 
M9 36.6 1.42 
M10 31.6 1.37 
M11 25.1 1.31 
         RNA integrity was also measured by agarose gel electrophoresis (Figure 33). The 
28S and 18S ribosomal RNA bands (upper two bands in each lane) of untreated and treated 
neutrophils had bright intensity. However, while 5S ribosomal RNA bands (lowest bands) 
were observed, they were diffuse as they were of lower molecular weight. 
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The 28S and 18S ribosomal RNA bands were fairly sharp, intense bands. The intensity of 
the upper band should be about twice that of the lower band. Smaller, more diffuse bands 
representing low molecular weight RNAs (tRNA and 5S ribosomal RNA) may be present. 
It is normal to see a diffuse smear of ethidium bromide staining material migrating between 
the 18S and 28S ribosomal bands, probably comprised of mRNA and other heterogeneous 
RNA species. DNA contamination of the RNA preparation would have been evident as a 
high molecular weight smear or band migrating above the 28S ribosomal RNA band, but 
this was not evident. Degradation of the RNA will be reflected by smearing of ribosomal 
RNA bands. However, ribosomal RNA bands were not present in NDMV lanes: M9, M10 
and M11. NDMV could cargo more small RNA with low molecular weight, such as 
microRNA. 
 
Figure 33. Total RNA integrity examination by agrose gel electrophoresis. Extracted RNA 
of untreated (N) and treated neutrophils (T) include 28S, 18S and 5S ribosomal RNA. 
Those specific ribosomal RNA were absent in neutrophils-derived microvesicles (M). Lane 






4.21 Characterisation of microRNA isolated from neutrophils and NDMV 
Micro-RNAs were isolated from untreated, control neutrophils (UN), neutrophils treated 
for 20 min with 50 ng/mL TNFα and from NDMV (prepared after treatment of neutrophils 
for 20 min with 50ng/mL TNFα, as described in Methods). After extraction of these 
microRNAs, they were sequenced, mapped and expression levels were compared between 
the three samples. The top 15 different expressions of microRNAs in comparisons are 
shown in (Table 10 and 11). Apart from identifying the range of microRNAs expressed in 
these three samples, comparisons were also made of those microRNAs that were up- or 
down-regulated between samples. Venn diagrams were used to visualize microRNAs that 
were differentially expressed between samples (Figure 34). These were compared as 
follows: A, upregulated microRNA in NDMV compared with untreated, control 
neutrophils (UN)-  220 microRNA; B, upregulated microRNA in NDMV compared with 
TNFα treated neutrophils (TN)- was 186 microRNA; C, upregulated microRNA in UN 
compared with TN- 125 microRNA; D, upregulated microRNA in TN compared to UN-  
122 microRNA.  Figure 34 shows overlapping section or microRNA among each 
microRNA groups. The covering area between ellipse A and B contained 159 microRNAs 
in Table 12. There were 128 microRNA from intersection of A and D excluded from the 
overlap of C and D sets.  The microRNAs, with low level in UN and TN, can still be loaded 
into NDMV. Overlapping 23 microRNAs of A and B ellipses were likewise enriched in 
UN than TN. However, the number of microRNA in intersection of A and B sets, enriched 
in TN and UN as well, was only 8. The 159 microRNAs, enclosed by NDMV, do not only 
up-regulate in comparison to untreated neutrophils, but also to TNFα treated neutrophils. 
These 159 microRNAs maintain high levels in NDMV regardless of that neutrophils were 
or not treated with TNFα. Total 159 enriched microRNAs were further analysed for target 




Note: A, up-regulated miRNA of NDMV vs untreated Neutrophils (N=3); B, up-
regulated miRNA of NDMV vs treated Neutrophils (N=3); C, up-regulated miRNA of 
untreated vs treated Neutrophils (N=3); D, up-regulated miRNA of treated vs untreated 
Neutrophils (N=3). 
Figure 34. Venn Images of upregulated microRNA among control, untreated neutrophils 
(UN), TNFα treated neutrophils (TN) and NDMV. The number in overlapping section 













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































4.22 Target genes prediction of NDMV-enriched microRNA  
To confirm the identity of the messenger RNA (mRNA) or gene expression pattern that 
was influenced by each microRNA, the binding sites of the 159 microRNAs enriched in 
NDMV, compared to neutrophils treated with TNFα, was predicted by analysis via two 
databases: TargetScan (Version 6.2) and miRDB (Version 4.0). The TarPmiR algorithm 
was used to improve the predicted precision and reliability based platform- miRWalk 2.0 
(http://mirwalk.umm.uni-heidelberg.de/) (Dweep and Gretz, 2015). Predicted microRNA 
targets were classified into validated and non-validated sub-groups by data resource-
miRTarBase.  
         Target genes, that were predicted by only one database alon  e (either TargetScan or 
miRDB), were excluded from further analyses. Predicted target genes, which were listed 
in both TargetScan and miRDB were used for next step analysis. In total, 657,394 genes 
were predicted by either resource alone, but 7,978 target genes were predicted in both 
TargetScan and miRDB. Of these, 1,258 target genes were further validated by 
miRTarBase. Figure 35 illustrates a network of 49 microRNAs interacting with their target 
gene and some of these    target genes are shared within the network. The 10 predicted 






Figure 35. Typical microRNA and their target genes predicted by TargetScan, miRDB and 
miRTarBase. There are 159 target genes were predicted by TargetScan, miRDB, but only 
predicted target genes of 49 microRNAs were available by miRTarBase. Orange dots 
represent microRNAs; violet dots represent predicted target genes. The selected pot shows 
microRNA name or its interactive gene name. The more violet pots interact with one 





































































































































































































































































































































































































































































































































































































































































































































































4.23 Gene ontology: molecular function (MF) of target genes 
The Gene Ontology (GO) project provides structured, controlled terms describing the 
functions of gene products, as well as the association of these terms with the gene products 
performing these functions. It is specifically designed for supporting the computational 
representation of biological systems (Ashburner et al., 2000, Acencio et al., 2019). It is 
categorized into three domains and associated annotations: molecular function (MF); 
biological process (BP) and cellular component (CC). 159 microRNAs were differently 
expressed in NDMV compared with both untreated neutrophils (ellipse A) and TNFα 
treated neutrophils (ellipse B), as shown in Figure 34 and Table 10. Furthermore, 7,978 
target genes of these 159 microRNAs were grouped with these three items, analysed by R 
packages: “systemPipeR”, “biomaRt” and “systemPipeRdata”. 
        For MF classification, 66 annotations of MF were found with significant differences 
(p<0.05). The top 25 significantly-different MF are shown in Figure 36. The most 
significant MF of target genes was protein binding (GO:0005515) with an adjusted p value 
of 1.7703×10-23 and highest enrichment score of 19.8745. There were 1562 target genes 
associated with this term, all of which interacted selectively and non-covalently with any 
protein or protein complex. The second most significant term of GO was DNA-
binding/transcription factor activity, RNA polymerase II-specific (GO:0000981) and was 
associated with 231 predicted genes. This term of MF involved a protein or a protein 
complex that interacts selectively and non-covalently with a specific DNA sequence 
(sometimes referred to as a motif) within the regulatory region of a RNA polymerase II-
transcribed gene to modulate transcription. Regulatory regions include promoters 
(proximal and distal) and enhancers. The third most significant term with p values of 
5.3332×10-20 was regulatory region nucleic acid binding (GO:0001067), and there were 
197 target genes involved in this term interacting selectively and non-covalently with a 
nucleic acid region that regulates a nucleic acid-based process. Such processes include 
transcription, DNA replication, and DNA repair. In summary, enriched microRNA in 
NDMV regulate a wide range of molecular functions: DNA transcription, mRNA 









4.24 Gene ontology: biological process (BP) of target genes  
475 terms of BP were found to be significantly enriched in NDMV (p<0.05). The top 25 
significantly different BP are shown in Figure 37 The terms with highest enrichment score 
(13.6949) in BP of target genes was nervous system development (GO:0007399), but the 
number of target genes interacted with NDMV microRNAs related to GO:0007399 was 
not highest for this term. The term of cellular process (GO:0009987) contained the most 
target genes (17,946). This term related to any process that is carried out at the cellular 
level, but not necessarily restricted to a single cell. For example, cell communication occurs 
in more than one cell such as cells to cells communication, but also occurs at the cellular 
level. The second and third most enriched BP processes were protein modification 
(GO:0036211) and cellular protein modification (GO:0006464) process. These two terms 
are related to the covalent alteration of one or more amino acids occurring in proteins, 
peptides and nascent polypeptides. In addition, metabolic processes were also highly 
enriched.   
 
 
Figure 37. Representative top 25 term with enrichment scores of BP for target genes. 
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4.25 Gene ontology: cellular components (CC) of target genes 
Significant differences were found in 81 terms of CC (p<0.05) with the top 25 significantly 
different CC are shown in Figure 38. The top 2 terms with highest enrichment scores were 
intracellular part (GO:0044424) and intracellular (GO:0005622) with enrichment scores of 
37.1 and 36.8, respectively. GO:0044424 is an obsolete term of CC, that has now been 
replaced by GO:0005622. The term intracellular or cellular component related to the living 
contents of a cell, contained within (but not including) the plasma membrane, usually taken 
to exclude large vacuoles and masses of secretory or ingested material. In eukaryotes, it 
includes the nucleus and cytoplasm. 
 
 







4.26 Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways of target genes 
To confirm potential interactions among microRNAs and molecules in cells, KEGG 
pathways were analysed.  7,978 target genes regulated by the 159 microRNAs were 
analysed by the R packages: “clusterProfiler”, “org.Hs.eg.db” and “enrichplot”. 
         In total, 101 KEGG pathways were significantly different (adjusted p < 0.05) and the 
top 25 significantly different pathways are shown in Figure 39A. Two major signaling 
pathways were identified as having the highest gene ratio (related target genes counts/total 
predicted target genes): PI3K-AKT and MAPK signaling pathways with gene ratios of 
0.0907 and 0.0833 (adjusted p=1.02×10-7 and 8.93×10-9). Gene ration was the number of 
target genes related to a specific signaling pathway divided by the number of total predicted 
target genes. This analysis identified 74 target genes interacting in the PI3K-AKT signaling 
pathway, and 68 target genes were involved in the MAPK signaling pathway. The third 
highest gene ratio identified (axon guidance) did not share any target genes with other top 
25 pathways (Figure 39B). The PI3K-AKT signaling pathway shared 26 target genes with 
the MAPK signaling pathway:  AKT3, MAPK1, KITLG, FGF7, IGF1, BDNF, VEGFC, 
HGF, NGF, FGF1, FASLG, NRAS, SOS1, ERBB4, NGFR, KIT, FGF2, IGF1R, EFNA1, 
PRKCA, FGFR2, MET, INSR, FGF17, IGF2 and TP53 (Figure 40 and Figure 41). In the 
Ras signaling pathway, with a gene ratio of 0.0612, the active Ras is capable to regulate 
cellular function through components of the PI3K-AKT and MAPK signaling pathways. 
Hyaluronic acid (HA) is an essential proteoglycan secreted by FLS, which was main 








Figure 39. KEGG pathways analysis of target genes. (A) Dotplot of top 25 pathways with 
lowest adjusted p value and highest genes ratios. (B) Network of top 25 pathways with 






Figure 40. The components involved in MAPK signaling pathway. Red boxes and text 
represent factors that interacted with NDMV microRNA. Green boxes and text represent 





Figure 41. The components involved in PI3K-AKT signaling pathway. Red boxes and text 
represent factors that interact with NDMV microRNA. Green boxes and text represent 





Part D: NDMV Effects on FLS function 
4.27 Effects of NDMV on FLS Viability 
To determine the viability of FLS after exposure to TNFα and NDMV, cellular metabolic 
activity was determined by the MTT assay. The viability of FLS treated with 10 ng/ml 
TNFα for 24h was not significantly different to that of untreated controls, incubated in the 
absence of TNFα. However, when FLS were exposed to NDMV at ratios of 200, 300 and 
400 per cell for 24h, the cell viabilities were decreased to 63%, 58% and 69%, respectively 
(p < 0.01). However, after incubation of FLS with NDMV at ratios of 10, 30, 50 and 100 
per FLS for 24h, there were no significant differences in viability compared to control 
(untreated) cells (Figure 42A).  
         The effect of incubation time on the viability of FLS following incubation with 
NDMV was then investigated. FLS were incubated with NDMV at a ratio of 100 NDMV 
per cell and at time periods, viability was measured by the MTT assay and compared to 
that of untreated controls. In the absence of NDMV, MTT activity increased in line with 
the increase in cell number (Figure 42B). FLS viability was unaffected by incubation with 
this concentration of NDMV for up to 24h incubation, but by 48h incubation, FLS viability 
was significantly decreased (p=0.0079, Figure 42B).  Therefore, in subsequent experiments, 
FLS were incubated with NDMV at a ratio of 1:100 for 24h as these experimental 











Figure 42. Cell viabilities of FLS incubated with different ratios of NDMV over time. (A) 
FLS were co-cultured TNFα alone (10 ng/mL) or NDMV at particle:cell ratios of 10, 30, 
50, 100, 200, 300, and 400 for 24 h. Control cell viability is designated as 100% for cells 
incubated in the absence of TNFα  after 24 h incubation. (B) Cell viabilities of FLS 
incubated in the absence (●) or presence (▲) of NDMV at a ratio of 1:100 over a 48h 
incubation period. Initial cell viability at time 0h is defined as 100%. Values shown are 
mean ± SE, N=5 separate experiments. Data analyzed with Wilcoxon test compared to 




4.28 NDMV effect on FLS immigration 
The scratch wound healing assay was used to measure NDMV effects on FLS migration 
and proliferation. Figure 43A shows captured images of FLS with/without NDMV 
treatment at time 0h, 24h and 48h culture. At 24h, a few FLS proliferated across the green 
line to the blank (scratched out) area in both the untreated and NDMV-treated samples. 
The wound healing area (WHA) of untreated cells was 26.83±2.98% which was higher 
than that of NDMV-treated which was 15.65±4.06%: these differences were not significant 
in Figure 43B (p=0.1598). After FLS monolayers were cultured ± NDMV for 48h, the 
WHA increased to 56.00±4.73% in untreated cells, whereas the WHA decreased into 
13.21±7.06% in FLS treated NDMV for 48h in Figure 43B (p=0.0079). Therefore, the 





Figure 43. Percentages of wound healing area (WHA) after synovial fibroblast monolayer 
scratching ± treatment with NDMV at 0h, 24h and 48h. Cell monolayers shown are 
representative from n=5 experiments (A). WHA percentages were quantified by the ImageJ 
software (B). Values shown were mean (±SE, N=5), Wilcox test was used for statistical 




4.29 FLS internalisation of NDMV by FLS: measurement by flow cytometry 
To measure and quantify uptake of NDMV by FLS, cells were co-cultured with PKH26-
labelled NDMV at a ratio of 1:100 for different time periods and then analyzed by flow 
cytometry. Uptake of labeled NDMV by FLS was detected as early as 0.5h after addition, 
increased by 6h incubation, but uptake was not increased further by 24 h incubation (Figure 
44A). After 1h incubation, 3.6% of FLS took up NDMV and by 6h incubation over 35% 
of the cells stained positive for NDMV uptake: by 24h incubation, 37% of the FLS stained 
positive.  Calculation of uptake as a fold change in MFI revealed a 1.25 increase by 0.5h 
(compared to vehicle control), rising to the 2.4-fold increase by 6h, which was largely 
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Figure 44. Measurement of NDMV uptake by flow cytometry. (A) Shows scatter plot of 
untreated, control FLS, and 1h, 6h and 24h after addition of NDMV at a ratio of 1:100. 
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The vertical line is the gating threshold to identify NDMV-negative and -positive FLS. 
The upper and right panels are density curves of target fluorescence in FLS and cell size. 
(B) The mean MFI fold change over time of incubation of FLS with labelled NDMV. 
Data were normalized to FLS in the absence of NDMV. Each point represents the mean 





4.30 FLS internalisation of NDMV by FLS: analysis by confocal microscopy 
Confocal microscopy was used to confirm uptake and internalisation of PKH26-labeled 
NDMV by FLS. Cells were incubated with NDMV for 24h and then stained for 
visualisation of the actin cytoskeleton using phalloidin and the nucleus using DAPI. Z-
stack images were then collected to reconstruct 3D images of the samples. This analysis 
revealed that single and multiple NDMV were localized in the cytoplasm of the FLS, in 
equivalent focal planes as the actin cytoskeleton (Figure 45A and B). This experimental 
approach confirmed that NDMV were internalised by FLS in a time-dependent manner: 
labeled NDMV was found inside of one FLS on 1h co-culture; but all FLS took NDMV up 
on 6h and 24h. (Figure 45C). The number of FLS internalized NDMV in a confocal image 
was quantified by the percentage of NDMV-labelled positive FLS. The percentage of 
positive FLS was in a time-dependent way: 25.94%, 94.16% and 94.64 for 1h, 6h and 24h, 











Figure 45. Visualisation of NDMV internalised within FLS by confocal microscopy. 
NDMV were incubated with FLS at a ratio of 100:1. (A) and (B) Show representative 
images of three-dimensional analysis after 24h incubation.  Nuclei were stained by DAPI 
(blue) and actin by phalloidin (green), whereas NDMV were labelled by PKH26 (red). 
Middle images are optical sections; upper and right panels are vertical cross sections (red 
and green lines) of NDMV from confocal Z stack series. (C) Representative images at 
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1h, 6h and 24h. Scale bar: 20μm.  (D) The number of FLS internalizing labelled NDMV 
was quantified into percentage of cells with MV normalized by total amount of FLS. 






4.31 NDMV effects on cytokines expression by TNFα-stimulated FLS 
We then measured the effects of NDMV on the ability of FLS to secrete a range of 
cytokines after incubation for 6h and 24 h in the presence and absence of TNFα. In these 
experiments, we determined the effects of NDMV alone on FLS cytokine expression and 
the ability of NDMV to affect TNFα regulated expression, after co-incubation of FLS with 
NDMV plus TNFα. Of the cytokines analysed, all except IL-1β, IL-7, IL-10, IL-12, IL-13 
and GM-CSF were detected in FLS culture medium, as the level of IL-7, IL-12 and IL-13 
were could not recorded by Multiplex system and low values obtained for IL-1β, IL-10 and 
GM-CSF were out detectable range and hence could not be reliably quantified. 
         The addition of TNFα alone significantly stimulated the secretion of IL-2, IL-4, IL-
5, IL-6, IL-8, IFNγ, MCP-1 and MIP-1 from FLS (p<0.05, Figure 46). TNFα also 
significantly elevated IL-17 and G-CSF expression by FLS, and while this increased 
expression was statistically significant, the magnitude of this increase was not as great as 
that for other cytokines and chemokines, largely because of more variable expression rates 
by unstimulated FLS.  The addition of NDMV alone to FLS for 6h and 24h had little effect 
on cytokine expression, except for a significant decrease in endogenous IL-6, IFNγ and 
MCP-1 expression. However, when co-incubated with TNFα, NDMV significantly 
decreased TNFα induced expression of IL-5, IL-6, IL-8, IL-17, G-CSF, IFNγ, MCP-1 and 
MIP-1 (p<0.05, Figure 46). In contrast, NDMV had no significant effect on TNFα induced 













Figure 46. Inflammatory cytokine and chemokine levels in FLS and NDMV co-culture 
supernatants. Cytokine levels after incubation as follows: control; + NDMV 6h - TNFα; 
+ NDMV 24h -TNFα; + NDMV 6h + TNFα; + NDMV 24h +TNFα and + TNFα. TNFα 
induces FLS to produce 10 cytokines, which are prohibited by NDMV pre-treatment. 
The cytokines inhibition of NDMV is significantly improved at 24h than 6h. Cytokine 
levels were analyzed with Conover test: dots (●) in box plots represent mean values (± 











4.32 Heatmap and cluster analysis of NDMV effects on cytokines expression  
Hierarchical cluster analysis via heatmaps demonstrated relationships between patterns of 
cytokine expression in the presence and absence of TNFα and NDMV (Figure 47). This 
demonstrates that cytokine expression in the absence of TNFα was largely unaffected by 
treatment with NDMV: control and NDMV exposure for 6h or 24h were lower and these 
clustered together. However, in the presence of TNFα and NDMV, the patterns of cytokine 
expression clustered, but two patterns were apparent: down-regulated expression of IL-17, 
G-CSF, IL-8, MIP-1β, MCP-1, IL-5, IL-6 and IFNγ after NDMV exposure for 6h and 24h, 







Figure 47. Heatmap of concentrations of inflammatory cytokines in cultured media of FLS 
with/without NDMV and TNFα. Median values were first standardized into z-score based 
on each cytokine level in different groups. The Hierarchical Method was then used for 
cluster analysis on this standardised data. Colour codes represent high (red), intermediate 








Chapter 5. DISCUSSION 
5.1 Characteristics of FLS 
In addition to FLS and MLS, synovial tissues contain various numbers and types of cells, 
such as lymphocytes, macrophages, endothelial cells, DC, etc. that had to be removed 
during the isolation of FLS prior to their culture and characterisation. Free cells in 
suspension (lymphocytes and granulocytes) could be removed by medium changes and 
sub-culture, but adherent cells (macrophages, MLS, endothelial cells and DC) were 
progressively eliminated from the cultures during successive passages and culture in vitro. 
Therefore, total numbers of cells usually decreased over the first few days (by day 4) in 
culture in P1 as these cells were progressively lost. However, we observed typical growth 
curve of P4 FLS showing an “S” shape curve of cell proliferation. Additionally, the 
doubling times of cells was higher in P4 than P1, which demonstrated higher proliferation 
rates in P1. However, the proliferation rates of FLS by two different isolation methods 
(explant and dispersed) were identical. Xiao et al. reported that high purity of FLS (<99%) 
could be obtained from dispersed cells culture compared to explant cultures(Xiao et al., 
2010). Both methods are acceptable to obtain FLS.  
         After dispersed cells were cultured in P1 to P4, the time of cellular confluency to 
achieve 85% were very comparable from 6.5 to 7.5 days in comparison of explant culture 
in P1 and P4. However, the time of 85% confluency was different between dispersed cells 
culture and explant culture, as enzymatic methods could effectively shorten process of 
“tissues to cells” from 14 days to 4 days. In this respect, the dispersed cell culture method 
resulted in cultures of high purity of FLS and well-preserved FLS characteristics, as well 
as a short culture period. As a result, the method of dispersing cells by two-enzymes 
(collagenase and trypsin) was used in our experiments. 
         To distinguish between FLS and MLS is often problematic by visualization on the 
light microscope, but the high density of rough Endoplasmic Reticulum (rER) present in 
132 
 
FLS can be detected by electron microscopy, which indicates high biosynthetic activity of 
these cells that secrete large quantities of molecules into the synovial joint. In addition to 
morphological properties of FLS detectable by EM, their membrane surface makers are 
different to those of MLS. The FLS positive markers are CD90 (Thymocyte differentiation 
antigen-1, Thy-1), CD55 (decay accelerating factor, DAF), CD106 (vascular cell adhesion 
molecule-1, VCAM-1), uridine diphosphoglucose dehydrogenase (UD-PGD) and vimentin 
(Zimmermann et al., 2000). CD90 and vimentin may also be expressed on mesenchymal 
stem/stromal cells (MSC) and fibroblasts that originate from other tissues (Peduto et al., 
2018). Fibroblasts of the sub-intimal layer also express CD55, CD106 and UD-PGD (Xiao 
et al., 2010).  The negative markers of FLS are positive markers for MLS, such as CD11b 
and CD64. In my experiments, CD55+ and CD90+ synoviocytes were the most prominent 
cells by passage 4 (83-85% CD55+, 98-99% CD90+,), while CD11b+ and CD64+ 
synoviocytes decreased to 1-2% and 5-6%, respectively, of the population by this time. 
         As FLS purity increased from P1 to P4, there were more synoviocytes in G0/G1 phase 
and fewer in S phase because long cell culture periods influence the cell cycle, proliferation, 
transcription factor activity and differentiation (Zimmermann et al., 2000). Gu et al. found 
that the percentage of human umbilical cord MSC in G1 phase increased as cell passage 
number increased, meanwhile, while those in S phase decreased, and the percentage in G2 
phase did not alter significantly (Gu et al., 2016). These researchers demonstrated that 
long-term primary culture could increase intracellular oxidative stress of cells to promote 
variations in the cell cycle. In addition, long-term primary culture could increase the 
probability of trisomy 7 in synoviocytes to affect cellular proliferation by Ki-67 protein 
(Ermis et al., 1995). Finally, long-term primary culture could induce accumulation of 
reactive oxygen species (ROS) and shorten telomere length during in vitro passage of FLS. 
Sun and his colleagues found that exogenous telomerase addition preserved FLS growth 
rate to maintain the population doubling time (Sun et al., 2004).  In our experiments, we 
observed that it was difficult to trypsinize P10 FLS and most of the recovered FLS did not 




5.2 Neutrophil function 
Isolation of functionally-competent neutrophils was a fundamental step for experiments 
aimed at preparing neutrophil-derived microvesicles (NDMV). Polymorphprep was used 
to isolate neutrophils from whole blood of healthy volunteers, a process that could be 
completed within 2 h. Thomas et al. indicated that Polymorphprep was a reliable method 
to obtain highly-pure neutrophils (purity > 95%)  and that  contaminating cells (< 5%) did 
not have a statistically-significant impact on general gene expression of TNFα treated 
neutrophils (Thomas et al., 2015). Neutrophil purity was over 98% in our experiments as 
indicated by microscopy and flow cytometry examinations. 
          As neutrophils were exposed to TNFα at a high dose (50ng/ml) and for a short time 
(20min) for the preparation of NDMV, it was important to determine the cell characteristics 
and functions after this TNFα exposure. Several neutrophil surface antigens can be up-
regulated (e.g. CD11b) or down-regulated (e.g. CD62L), after exposure to TNFα 
(Wittmann et al., 2004, Headland et al., 2015). These receptors are crucial for neutrophil 
adhesion, recruitment and migration. In addition, increased CD11b on neutrophils can 
interact with CD54/Intercellular Adhesion Molecule 1 of endothelial cells to increase 
neutrophil accumulation in inflammatory foci (Krieger et al., 2004). However, CD62L on 
the neutrophil surface is decreased after TNFα treatment, by activating Tumor Necrosis 
Factor-α-Converting Enzyme (TACE) via the p38 MAPK pathway (Ivetic, 2018, Killock 
and Ivetic, 2010). CD62L on neutrophils normally controls rolling on and off the 
endothelial bed, but its shedding triggers tighter adhesion with the endothelium. 
         Wittmann et al. demonstrated that CD11b up-regulation and CD62L down-regulation 
were associated with TNFα priming and fMLP stimulation of the neutrophil respiratory 
burst (Wittmann et al., 2004). In our experiments, high-dose TNFα primed neutrophils 
were further stimulated by fMLP and PMA to produce ROS (Reactive Oxygen Species), 
that were higher than after TNFα treatment alone. Moreover, ROS induced by PMA was 
higher than fMLP, as fMLP required Formyl Peptide Receptor 1/2 (FPR1/2) while PMA 
is a phorbol ester that is transported passively across the cell membrane (Tan et al., 1998, 
Thomas et al., 2000, He and Ye, 2017). Barnes et al. (2012) also reported that low-dose 
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TNFα primed neutrophils generated more ROS after both fMLP and PMA stimulation than 
in control (non- TNFα) group (Barnes et al., 2012).  
         It was then necessary to determine whether this TNFα treatment induced changes in 
other neutrophil functions. The first of these tested was the effect on apoptosis. It was found 
that high-dose and short-time incubation with TNFα only induced about 1% of the 
neutrophils to undergo apoptosis. When incubated in vitro, around 60% of neutrophils 
undergo apoptosis by 24h  (Savill et al., 1990), and previous research found that high-dose 
TNFα (10ng/ml and 100ng/ml) and low-dose (1ng/ml) induced neutrophil apoptosis after 
overnight and 3h incubation (van den Berg et al., 2001, Takeda et al., 1993). However,  
another study showed that different concentrations of TNFα (1, 10 and 100ng/ml) could 
not significantly affect neutrophil apoptosis after 1-2min incubation (Salamone et al., 
2001). They likewise showed that 10ng/ml TNFα induced neutrophil apoptosis by 0.5, 1 
and 3h. Furthermore, Cross et al. showed that TNFα possessed dual features on neutrophil 
apoptosis in a dose-dependent manner (Cross et al., 2008); low-dose TNFα (1ng/ml) had 
an anti-apoptotic role on neutrophils by inducing Bfl-1 while high-dose TNFα (10ng/ml 
and 100ng/ml) promoting neutrophil apoptosis by Mcl-1 degradation after 2, 3 and 6h 
exposures. However, 10ng/ml TNFα could induce anti-apoptotic gene expression by 
neutrophils after 1h exposures (and 3h and 6h) (Chiewchengchol et al., 2016). In my 
experiments, 50ng/ml of TNFα was used to treat neutrophils for 20min to generate MV 
and this was not shown to induce morphological changes associated with apoptosis, 
supporting previous publications (Headland et al., 2015, Rhys et al., 2018, Dalli et al., 
2008).  
          Neutrophil migration was suppressed by TNFα pretreatment in our experiments. In 
fact, fMLP and TNFα were effective chemoattractants for neutrophils and induced 
polarization, adherence and transmigration. It has been shown that TNFα-induced 
adherence and migration was blocked by PI3K and MAPK inhibitors (Kamata et al., 2004, 
Suzuki et al., 2001). However,  TNFα blocked the capability for cytoskeleton 
reorganisation of neutrophils which may result in decreased neutrophil chemotaxis induced 
by fMLP (Kutsuna et al., 2004, Kato and Kitagawa, 2006). Therefore, it can be concluded 




5.3 Properties of NDMV 
The various types of EV that are produced and shed from donor cells are categorized by 
size, composition and assembly mechanism. EV classification is based on their size, but 
there is considerable overlap in sizes of different types of EV and their actual sizes may be 
dependent on the method of isolation and purification (Van der Pol et al., 2014, Van der 
Pol et al., 2016, Arraud et al., 2014). The conventional method to isolate EV is 
centrifugation and it has been reported that NDMV-enriched fractions can be prepared by 
centrifugation at 20,000 or 15,700 ×g (Pliyev et al., 2014, Rhys et al., 2018). However, 
NDMV are usually prepared by ultra-centrifugation at 100,000 ×g, conditions that we used 
in our study (Table 2.5.3). Electron microscopy is a standard method to measure EV size 
to identify the EV type.  EV are irregular spheres under electron microscopy, and EV can 
be used to measure maximum and minimum diameters. The minimum, maximum and 
average diameters of EV measured by TEM were larger by those measured by SEM. This 
could be a varying result from the different sample preparations, as EV samples were 
dehydrated with series of solvent for each of 5min (acetone and ethanol). The EV diameter 
measured by TEM was 80 nm, which was larger than the average measured by SEM. 
However, all EV average diameters were >100nm as measured by TEM. NTA confirmed 
these findings: analysis of these vesicles by NTA showed that 97-98% of isolated NDMV 
were in the size range of 100-1000nm. Therefore, the morphology and size characteristics 
of NDMV in our experiments were consistent with our expectations and previous reports 
(Ajikumar et al., 2019, Finkielsztein et al., 2018). 
         TNFα can stimulate neutrophils to change the surface expression of CD markers and 
receptors through degranulation and shedding (Galligan and Yoshimura, 2003). Neutrophil 
granules comprise 4 types: primary/azurophil granules (CD63+, CD68+), 
secondary/specific granules (CD11b+, CD15+, CD66+, CD67+), tertiary/gelatinase 
granules (CD11b+) and secretory vesicles (CD11b+, CD14+, CD10+, CD13+, CD45+). 
Expression of CD66 and CD14 were not significantly different between MV and untreated 
control neutrophils (Vols et al., 2017, Lawrence et al., 2018). Expression of CD66 and 
CD14 were not significantly different between MV and untreated control neutrophils 
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(Elbim et al., 2001, Galligan and Yoshimura, 2003, Rørvig et al., 2013). Secretory vesicles 
contain CD14 which binds lipopolysaccharide (LPS) to increase TNFα production and 
release by neutrophils (Takeshita et al., 1998, Ishii et al., 1993). Niel et al. demonstrated 
that melanocyte-derived exosomes could express CD63, which could modulate endosomal 
arrangement that is dependent upon the Endosomal Sorting Complex Required for 
Transport (ESCRT) process (Van Niel et al., 2011, van Niel et al., 2018). Primary granules 
contain abundant MPO, which was one protein present in EV (Dalli et al., 2013, Vols et 
al., 2017). We demonstrated that NDMV expressed surface markers from primary and 
tertiary granules of neutrophils.  Dali et al. reported in their proteomic supplementary data 
that Annexin V also was abundant on NDMV in their proteomic supplementary data (Dalli 
et al., 2013). which was consistent with our flow cytometry results which showed that more 
Annexin V was expressed on NDMV than on treated and untreated neutrophils. The 
function of Annexin V on NDMV and the role that this may play on recipient cells is 
unknown. Vascular smooth muscle, chondrocytes, osteoblasts and macrophages have all 
been shown to generate MV or matrix vesicles expressing Annexin V (Kapustin et al., 2011, 
New et al., 2013, Xiao et al., 2007, Genge et al., 2007). These MV with abundant Annexin 
V may bind with phosphatidylserine and/or S100A9 to develop a nucleation complex for 
physiological calcification and matrix mineralization (Krohn et al., 2016). 
 
5.4 NDMV carried microRNAs 
There were 159 predominant microRNAs detected in NDMV prepared which were 
released from TNFα treated neutrophils which contained 220 microRNAs compared to 
untreated cells. 5% of microRNAs were identical in TNFα treated neutrophils and 
untreated cells. 18% microRNAs overlapped with up-regulated microRNAs from untreated 
neutrophils compared treated cells. Squadrito et al. found that microRNAs were not 
randomly loaded in EV, but selectively loaded into macrophage-derived EV in response to 
various forms of macrophage activation (Squadrito et al., 2014). In total, 657,394 genes 
were predicted to interact with the 159 microRNAs identified in our NDMV preparations, 
and the target genes included protein- or DNA-binding, proteins or metabolic process and 
intracellular components. NDMV could profoundly influence FLS by their microRNA.  
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         EV incorporated microRNAs are a way to transport such molecules to target cells 
and avoiding RNase degradation in extracellular fluids. Thus, microRNAs within EVs 
retain their integrity and activation potential that would persist until internalization by the 
target cells (Turturici et al., 2014, Asghar et al., 2019). Alexander et al. (2015) found that 
MV contained microRNA-155 and microRNA-146a that could be internalized by marrow-
derived DCs whose microRNA-155 and 146a levels were then elevated to detectable levels 
in mouse model (Alexander et al., 2015). In this study, TNFα and IL-6 concentrations were 
regulated by these microRNA-loaded EV. However, NDMV in our experiments did not 
contain these two microRNA, rather microRNA-3168, 4488, 124-3p, 10398-3p, 1290 and 
6968-5p in NDMV were increased in TNFα-exposed neutrophils by 2-fold. 
 
5.5 PI3K/AKT and MAPK signaling pathways may be regulated by NDMV 
microRNA 
PI3K-AKT and MAPK were the two most significant signaling pathways that were 
predicted to be regulated by predicted target genes of NDMV microRNAs according to the 
KEGG database. PI3K-AKT is a crucial pathway that contributes to the inflammatory 
response, cell growth or proliferation and cellular apoptosis (Lu and Qian, 2019, Huang et 
al., 2019, Li et al., 2018). The activation of PI3K-AKT could induce the downstream 
pathway,  Nuclear Factor kappa-light-chain-enhancer of activated B cells (NF-κB) to 
regulate inflammatory cytokine expression and the p53 signaling pathway to regulate gene 
expression (Schabbauer et al., 2004). PI3K-AKT activation could also initiate mTOR 
which would stimulate NF-κB to up-regulate inflammatory gene expression, especially, 
including iNOS, COX-2, IL etc. (Shabab et al., 2017). The MAPK signaling pathway is 
also important in the regulation of inflammatory cytokine expression via NF-κB and Jun 
in FLS (Du et al., 2019, Rosillo et al., 2019, Namba et al., 2017). Previous work has 
demonstrated that exogenous microRNAs (microRNA-145, 143-3p or 451) modulated pro-
inflammatory cytokines (TNF-α, IL-1β or IL-6) through PI3K/AKT and MAPK/mTOR 




5.6 NDMV effect on FLS 
In this thesis, we have isolated NDMV from TNFα treated human neutrophils and 
measured their effects on the function of FLS prepared from OA synovium, especially the 
ability of FLS to express cytokines and chemokines that can promote synovitis. We show 
that NDMV can inhibit the expression of a variety of pro-inflammatory molecules that are 
released by FLS following stimulation with TNFα. Our data thus add to the growing body 
of evidence to show that, under certain experimental and perhaps disease conditions, 
NDMV exert anti-inflammatory effects. 
         NDMV expressed annexin A1, CD66b, CD62L on their cell surface (as do intact 
neutrophils) and myeloperoxidase (MPO) in line with previous publications (Headland et 
al., 2015, Pitanga et al., 2014). MPO is an efficient peroxidase that may elicit oxidative 
damage and produce cytotoxic hypochlorous acid (HOCl) and other oxidants in 
inflammatory conditions (Pattison and Davies, 2006). MPO has been detected in synovial 
fluid of OA patients and is elevated in RA patients, and intra-articular injection of MPO 
increased the severity of arthritis in a mouse model (Nzeusseu Toukap et al., 2014, 
Lefkowitz et al., 1999). Internalised NDMV could induce MPO accumulation and 
intracellular activity that might interfere with FLS viability, proliferation and migration. 
The scratch-wound assay showed that NDMV slowed down FLS migration, as indicated 
by a decrease in the wound healing area. However, high-dose (V/C>100) and long-term 
(>24h) NDMV treatments were harmful to FLS viability and biological activity. The 
mechanisms of NDMV that result in internalisation generally include endocytosis, 
micropinocytosis, phagocytosis or membrane fusion etc. (Mulcahy et al., 2014). 
Endocytosis is a major mechanism of EVs uptake by recipient cells into the endosomal 
compartment which may then be transported to lysosomes (Lázaro-Ibáñez et al., 2017, 
Tian et al., 2013, Montecalvo et al., 2012). EVs internalisation is dependent on EVs dose, 
treatment time and the nature of the recipient cells. In our experiments, NDMV internalised 
by FLS with approximately 35% of cells taking up labelled NDMV over a 6 h to 48h period.  
         As a member of the pro-inflammatory family of cytokines, TNFα is generated by 
cells such as neutrophils, macrophages or adipocytes to induce systemic inflammation 
(Bulló et al., 2003). TNFα has been detected in synovial fluid, plasma and synovial 
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membrane of OA patients, and may activate both tissue cells and infiltrating immune cells 
(Mabey et al., 2016, Kapoor et al., 2011, Han et al., 2001, Stannus et al., 2010). NDMV 
have been shown to possess anti-inflammatory activity and promote inflammatory 
resolution, and in our experiments, NDMV could depress most inflammatory cytokines 
expressed by TNFα activated FLS (L Johnson et al., 2014). While IL-7, IL-12 p70 and IL-
13 expression was undetectable, IL-5, IL-6, IFN-γ and MCP-1 expression levels were not 
significantly different between control and TNFα treated FLS. However, expression of 
these latter 4 pro-inflammatory cytokines were decreased by NDMV in non-activated FLS 
(Muhl and Pfeilschifter, 2003, Finnerty et al., 2006). This finding was contradictory to that 
of Mesri et al. (1999) who reported that IL-6 and MCP1 were elevated by NDMV via JNK1 
signaling pathway in endothelial cells (Mesri and Altieri, 1999). Our experiments suggest 
that the effects of NDMV are dependent on the nature and function of the target cells, or 
that the effects are dose and time-dependent. Expression of the pro-inflammatory 
chemokine, IL-8 was suppressed by NDMV pre-treatment of TNFα-activated FLS 
activator for 24h. Previous research has also shown that NDMV could decrease IL-8 
secretion by macrophages activated with zymosan or LPS (Gasser et al., 2003). The three 
family members of receptor tyrosine kinases (RTKs) - Tyro3, AXL and MER (TAM) - 
could be activated through binding with phosphatidylserine (PtdSer) which was carried on 
NDMV. Moreover, the FLS and synovial micromass (composition of macrophages and 
FLS at a ratio of 1 to 5) expressed these three TAM which decreased pro-inflammatory 
cytokines expression by up-regulation of the suppressor of cytokine signaling (SOCS) 
protein 1 and 3 (Rhys et al., 2018, Ruiz-Heiland et al., 2014, Waterborg et al., 2018a, 
Waterborg et al., 2018b). IL-1β is a classical pro-inflammatory cytokine whose levels are 
also increased in synovium and synovial fluid of OA patients. Rhys et al. (2018) found that 
NDMV-carried phosphatidylserine that could bind with its receptors MER (MER tyrosine 
kinase) of macrophages to block IL-1β expression via phosphoinositide 3-kinase (PI3K) 
and signal transducer and activator of transcription 1 (STAT1) signaling pathway (Rhys et 
al., 2018). NDMV prevented IL-1β produced by TNFα stimulated FLS at both 6h and 24h 
in our study, which might result from regulation of the TAM-SOCS signaling axis. 
          Additionally, we found that NDMV did not decrease IL-10 secretion but TNFα 
prevented FLS from releasing more IL-10 into culture supernatants, which was blocked by 
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NDMV pre-treatment. Pro-inflammatory levels of IL-17 levels are elevated in serum, 
synovial fluid and inflamed synovium in OA and are associated with disease severity 
(Deligne et al., 2015, Chen et al., 2014). IL-17 can enhance MMPs expression and up-
regulate expression of the pro-inflammatory cytokines: IL-1β, IL-6, IL-8 and TNFα in FLS 
from OA patients (Honorati et al., 2006, Agarwal et al., 2008). Interestingly, NDMV could 
up-regulate IL-17 levels released from FLS, but this effect was depressed in the presence 
of TNFα which increased IL-17 expression after 24h incubation. The anti-inflammatory 
cytokine, IL-4 was not altered in FLS stimulated with NDMV in the absence of TNFα, 
similarly to the pro-inflammatory IL-2. However, IL-4 expression decreased in FLS 
incubated with NDMV in the presence of TNFα by 24h incubation (but not by 6h), 
suggesting that NDMV do not only regulate expression of inflammatory cytokines, but also 
cytokines such as IL-4 that play regulatory roles in immune and inflammatory function. 
TNFα up-regulated expression of M-CSF and GM-CSF in our experiment, in line with 
previous reports (Watanabe et al., 2017), but GM-CSF secretion was significantly higher 
in NDMV 24h pre-treatment plus TNFα stimulation than TNFα treatment alone in this 
study. Furthermore, NDMV might probably modulate FLS via their carried an amount of 
microRNA cargo, because there microRNAs could up and down-regulate gene expression 
and translation, such as TNFα-related kinases (Valinezhad Orang et al., 2014).  
 
5.7 Limitation of this study 
Although FLS of high purity were successfully obtained by enzymatic primary culture, 
highly-pure neutrophils were efficiently separated from whole blood of volunteers and 
NDMV were effectively isolated from neutrophils, several limitations of this study should 
be clearly stated. This study is a descriptive research to investigate NDMV effects on FLS 
rather than mechanistic research, that could, for example use inhibitors or microRNA 
mimics to define the underlying molecular processes. It is impossible to investigate one 
specific protein or RNA function in the target cells, as NDMV are “information packages” 
with multiple components. Synovitis in the patients from whom we obtained the samples, 
could be in different phases of arthritis and influenced by systemic and local factors. MV 
are rarely released from untreated/healthy neutrophils, and so this study did not contain a 
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control group of microvesicles derived from healthy neutrophils. In the microRNA 
sequencing experiments, cells and NDMV were collected from 3 samples and for the 
NDMV microRNA experiments, those with low mapping rate were excluded from analysis. 
Clearly, such low abundance microRNAs may still have biological significance. 
Furthermore, in vivo, synovitis is likely to be associated with, and induced by several 
different mediators, but this in vitro study we modelled cellular inflammation in FLS by 
use of a single cytokine: TNFα. This research work did not include animal models of 
synovitis to verify the cell-based conclusions. Finally, only 17 inflammatory cytokines 






Chapter 6. CONCLUSIONS AND OUTLOOK 
In conclusion, in addition to their potential role in cartilage function to benefit 
chondrocytes and cartilage repair, NDMV were capable of controlling inflammatory 
responses of FLS through direct contact with macrophages to upload Annexin A1 and 
phosphatidylserine (PS) (Headland et al., 2015, Headland and Norling, 2015, Rhys et al., 
2018). Large quantities of NDMV were produced by non-apoptotic neutrophils stimulated 
by high dose, short term TNFα and their surface proteins, Annexin A1 or A5, PS, CD11b 
and CD63, may bind with ligands of FLS to initiate endocytosis to internalize NDMV. 
Various types of microRNAs were contained within NDMV that may be liberated in the 
cytoplasm of FLS by lysosomes to regulate gene expression, such as binding to target 
mRNAs to initiate post-transcriptional control. PI3K-AKT and MAPK signaling pathways, 
two classical and inflammation-related signaling pathways, were predicted to be most 
significant regulated by NDMV-carried microRNA. Inhibition of these pathways would 
prevent downstream signaling pathway, such as NF-κB and p53 signaling pathways, to 
decrease cytokine and chemokine expression, such as IL-6, IFNγ, MCP-1 etc. Our 
experimental work supported previous studies that demonstrated NDMV possess anti-
inflammatory properties to suppress inflammatory responses of FLS. Figure 48 suggests 
possible mechanisms and pathways regulated by NDMV. Our work encourages further 
studies to reveal mechanisms of how NDMV limit inflammation of the synovium and 





Figure 48. Possible mechanisms of NDMV inhibition of inflammatory responses of FLS 
via NDMV uploaded microRNA targeting PI3K-AKT and MAPK signaling pathway.          
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          In spite of the interest in EV and NDMV, there are still many unsolved questions to 
explore and investigate. EV are the “inflammation packages” composed of “good guys” 
and “bad guys”, so EV influences on target cells depend on resultant overall balance of all 
of their contents and components and the nature of the target cell. A major factor will be 
the efficiency with which they are internalized by the target cell. NDMV could be a suitable 
biomarker to improve precision of diagnosis and a suitable experimental tool for correction 
of inflammatory disease, especially in arthritis. Further work is needed to confirm if 
NDMV will be a potential approach to protect cartilage degradation and suppress synovitis 
in OA and RA. By identifying how stimulants facilitate neutrophils to generate MV and by 
characterising how NDMV modulate recipient cells via their uploaded components, could 
enable researchers and doctors to use NDMV in clinical practice for alleviating patient’s 
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Appendix A / KOOS: Knee Injury and Osteoarthritis Outcome Score 
This survey asks for your view about your knee.  
 
Symptoms 
These questions should be answered thinking of your knee symptoms during the last 
week. 
S1. Do you have swelling in your knee? 
Never Rarely Sometimes Often Always 
S2. Do you feel grinding, hear clicking or any other type of noise when your knee 
moves? 
Never Rarely Sometimes Often Always 
S3. Does your knee catch or hang up when moving? 
Never Rarely Sometimes Often Always 
S4. Can you straighten your knee fully? 
Always Often Sometimes Rarely Never 
S5. Can you bend your knee fully? 
 
Stiffness 
The following questions concern the amount of joint stiffness you have experienced 
during the last week in your knee. Stiffness is a sensation of restriction or slowness in the 
ease with which you move your knee joint. 
S6. How severe is your knee joint stiffness after first wakening in the morning? 
None Mild Moderate Severe Extreme 
S7. How severe is your knee stiffness after sitting, lying or resting later in the day? 
None Mild Moderate Severe Extreme 
 
Pain 
P1. How often do you experience knee pain? 
Never Monthly Weekly Daily Always 
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What amount of knee pain have you experienced the last week during the following 
activities? 
P2. Twisting/pivoting on your knee 
None Mild Moderate Severe Extreme 
P3. Straightening knee fully 
None Mild Moderate Severe Extreme 
P4. Bending knee fully 
None Mild Moderate Severe Extreme 
P5. Walking on flat surface 
None Mild Moderate Severe Extreme 
P6. Going up or down stairs 
None Mild Moderate Severe Extreme 
P7. At night while in bed 
None Mild Moderate Severe Extreme 
P8. Sitting or lying 
None Mild Moderate Severe Extreme 
P9. Standing upright 
None Mild Moderate Severe Extreme 
 
Function, daily living 
The following questions concern your physical function. By this we mean your ability to 
move around and to look after yourself. For each of the following activities please 
indicate the degree of difficulty you have experienced in the last week due to your knee. 
A1. Descending stairs 
None Mild Moderate Severe Extreme 
A2. Ascending stairs 
None Mild Moderate Severe Extreme 
For each of the following activities please indicate the degree of difficulty you have 
experienced in the last week due to your knee. 
A3. Rising from sitting 
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None Mild Moderate Severe Extreme 
A4. Standing 
None Mild Moderate Severe Extreme 
A5. Bending to floor/pick up an object 
None Mild Moderate Severe Extreme 
A6. Walking on flat surface 
None Mild Moderate Severe Extreme 
A7. Getting in/out of car 
None Mild Moderate Severe Extreme 
A8. Going shopping 
None Mild Moderate Severe Extreme 
A9. Putting on socks/stockings 
None Mild Moderate Severe Extreme 
A10. Rising from bed 
None Mild Moderate Severe Extreme 
A11. Taking off socks/stockings 
None Mild Moderate Severe Extreme 
A12. Lying in bed (turning over, maintaining knee position) 
None Mild Moderate Severe Extreme 
A13. Getting in/out of bath 
None Mild Moderate Severe Extreme 
A14. Sitting 
None Mild Moderate Severe Extreme 
A15. Getting on/off toilet 
None Mild Moderate Severe Extreme 
For each of the following activities please indicate the degree of difficulty you have 
experienced in the last week due to your knee. 
A16. Heavy domestic duties (moving heavy boxes, scrubbing floors, etc) 




A17. Light domestic duties (cooking, dusting, etc) 
None Mild Moderate Severe Extreme 
 
Function, sports and recreational activities 
The following questions concern your physical function when being active on a higher 
level. The questions should be answered thinking of what degree of difficulty you have 
experienced during the last week due to your knee. 
SP1. Squatting 
None Mild Moderate Severe Extreme 
SP2. Running 
None Mild Moderate Severe Extreme 
SP3. Jumping 
None Mild Moderate Severe Extreme 
SP4. Twisting/pivoting on your injured knee 
None Mild Moderate Severe Extreme 
SP5. Kneeling 
None Mild Moderate Severe Extreme 
 
Quality of Life 
Q1. How often are you aware of your knee problem? 
Never Monthly Weekly Daily Constantly 
Q2. Have you modified your lifestyle to avoid potentially damaging activities 
to your knee? 
Not at all Mildly Moderately Severely Totally 
Q3. How much are you troubled with lack of confidence in your knee? 
Not at all Mildly Moderately Severely Extremely 
Q4. In general, how much difficulty do you have with your knee? 




Appendix B / ISOA: Indices of Severity and Disease Activity for Osteoarthritis  
Sections for index:(1) Pain or discomfort; (2) Maximum distance walked; (3) Activities 
of daily living. 
 
Pain or Discomfort 
Parameter  Finding  Points 
Pain or discomfort during nocturnal bed 
rest 
None  0 
Only on movement or in 
certain positions 
1 
Without movement 2 
Duration of morning stiffness or pain 
after getting up 
None  0 
< 15 minutes 1 
>= 15 minutes 2 
Remaining standing for 30 minutes 
increases pain 
No  0 
Yes 1 
Pain on walking  
None  0 
Only after walking some 
distance 
1 
Early after starting  2 
Pain or discomfort after getting up from 
sitting without use of arms 
No  0 
Yes 1 
 
Maximum Distance Walked 
Parameter  Finding  Points 
Maximum distance walked 
Unlimited  0 
> 1 kilometer but limited 1 
About 1 kilometer (about 15 minutes) 2 
About 500 - 900 meters (about 8-15 
minutes) 
3 
From 300 - 500 meters  4 
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From 100 - 300 meters  5 
< 100 meters 6 
Walking aids required  
None  0 
1 walking stick or crutch  1 
2 walking sticks or crutches  2 
 
 Activities of Daily Living 
Parameter  Finding  Points 
Able to climb up a standard flight of stairs 
Easily  0 
With mild difficulty  0.5 
With moderate difficulty  1.0 
With marked difficulty  1.5 
Impossible  2.0 
Able to climb down a standard flight of 
stairs 
Easily  0 
With mild difficulty  0.5 
With moderate difficulty  1.0 
With marked difficulty  1.5 
Impossible  2.0 
Able to squat or bend at the knee  
Easily  0 
With mild difficulty  0.5 
With moderate difficulty  1.0 
With marked difficulty  1.5 
Impossible  2.0 
Able to walk on uneven ground  
Easily  0 
With mild difficulty  0.5 
With moderate difficulty  1.0 
With marked difficulty  1.5 




Appendix C / WOMAC: Western Ontario and McMaster Universities Arthritis Index 
The WOMAC consists of 24 items divided into 3 subscales: pain (5 items); stiffness (2 
items); physical function (17 items). The WOMAC is available in 5-point Likert-type and 
100mm Visual Analog formats. 
 
Section A: pain  
Think about the pain you felt during the last 48 hours caused by the arthritis in your knee 
or hip. Select the number that best describes your pain. Question: How much pain have 
you had:  
item None Mild Moderate Severe Extreme 
1. When walking in a flat surface?  0 1 2 3 4 
2. When going up or down stairs?  0 1 2 3 4 
3. At night while in bed? (that is 
pain that disturbs your sleep)  
0 1 2 3 4 
4. While sitting or lying down?  0 1 2 3 4 
5. While standing?  0 1 2 3 4 
 
Section B: stiffness 
Think about the stiffness (not pain) you felt during the last 48 hours caused by the arthritis 
in your knee or hip. Stiffness is a sensation of decreased ease in moving your joint. Select 
the number that best describes your stiffness:  
item None Mild Moderate Severe Extreme 
6. How severe has your stiffness 
been after you first woke up in the 
morning?  
0 1 2 3 4 
7. How severe has your stiffness 
been after sitting or lying down or 
while resting later in the day?  
0 1 2 3 4 
 
Section C: difficulty performing daily activities 
Think about the difficulty you had in doing the following daily physical activities during 
the last 48 hours caused by the arthritis in your knee or hip. By this we mean your ability 
to move around and take care of yourself. Select the number that best describes your 




item None Mild Moderate Severe Extreme 
8. when going down the stairs?  0 1 2 3 4 
9. when going up the stairs?  0 1 2 3 4 
10. when getting up from a sitting 
position?  
0 1 2 3 4 
11. while standing?  0 1 2 3 4 
12. when bending to the floor?  0 1 2 3 4 
13. when walking on a flat surface?  0 1 2 3 4 
14. getting in or out of a car, or 
getting on or off a bus?  
0 1 2 3 4 
15. while going shopping?  0 1 2 3 4 
16. when putting on your socks or 
panty hose or 
stockings?  
0 1 2 3 4 
17. when getting out of bed?  0 1 2 3 4 
18. when taking off your socks or 
panty hose or stockings?  
0 1 2 3 4 
19. when lying in bed?  0 1 2 3 4 
20. when getting in or out of the 
bathtub?  
0 1 2 3 4 
21. while sitting?  0 1 2 3 4 
22. when getting on or off the toilet?  0 1 2 3 4 
23. while doing heavy household 
chores?  
0 1 2 3 4 
24. while doing light household 
chores?  





Appendix D / Heatmaps of microRNA Different Expression in Neutrophils and 
NDMV 
 
















Appendix E / Reactome Pathway Analysis of NDMV microRNA 
Reactome is an open pathway database for bioinformatic analysis (https://reactome.org). It 
provides another available approach to process big data of target gene. We used the 
analysed results of Reactome pathway to compare with that of KEGG. The following table 
shows probable pathway (p < 0.05) related with NDMV microRNA of 159. Red words in 
description were related to PI3K-AKT and MAPK signaling pathway. 
 
Table E.  Reactome pathway of NDMV microRNA 
ID Description GeneRatio qvalue 
R-HSA-9006934 Signaling by Receptor Tyrosine Kinases 93/1156 5.74735E-06 
R-HSA-112316 Neuronal System 74/1156 0.001242358 
R-HSA-5663202 Diseases of signal transduction 69/1156 0.001242358 
R-HSA-9006925 Intracellular signaling by second messengers 54/1156 0.006055974 
R-HSA-5683057 MAPK family signaling cascades 54/1156 0.003584897 
R-HSA-9006931 Signaling by Nuclear Receptors 49/1156 0.029773722 
R-HSA-9607240 FLT3 Signaling 49/1156 0.005510192 
R-HSA-112315 Transmission across Chemical Synapses 45/1156 0.032398328 
R-HSA-1257604 PIP3 activates AKT signaling 45/1156 0.022315083 
R-HSA-5684996 MAPK1/MAPK3 signaling 42/1156 0.040735265 
R-HSA-5673001 RAF/MAP kinase cascade 42/1156 0.031485128 
R-HSA-8939211 ESR-mediated signaling 40/1156 0.016671707 
R-HSA-1483257 Phospholipid metabolism 37/1156 0.030933667 
R-HSA-397014 Muscle contraction 37/1156 0.027731091 
R-HSA-112314 
Neurotransmitter receptors and postsynaptic signal 
transmission 37/1156 0.022315083 
R-HSA-6811442 Intra-Golgi and retrograde Golgi-to-ER traffic 36/1156 0.027785156 
R-HSA-5576891 Cardiac conduction 28/1156 0.019287451 
R-HSA-73887 Death Receptor Signaling 27/1156 0.030933667 
R-HSA-194840 Rho GTPase cycle 26/1156 0.040476774 
R-HSA-166520 Signaling by NTRKs 26/1156 0.001954227 
R-HSA-2219528 PI3K/AKT Signaling in Cancer 26/1156 0.001954227 
R-HSA-199418 Negative regulation of the PI3K/AKT network 25/1156 0.007607503 
R-HSA-9006936 Signaling by TGF-beta family members 25/1156 0.003584897 
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R-HSA-6811558 PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling 23/1156 0.012211791 
R-HSA-5173105 O-linked glycosylation 22/1156 0.042165819 
R-HSA-187037 Signaling by NTRK1 (TRKA) 22/1156 0.001954227 
R-HSA-442755 Activation of NMDA receptors and postsynaptic events 21/1156 0.015713737 
R-HSA-193704 p75 NTR receptor-mediated signaling 20/1156 0.040476774 
R-HSA-74752 Signaling by Insulin receptor 20/1156 0.006055974 
R-HSA-9009391 Extra-nuclear estrogen signaling 20/1156 0.005510192 
R-HSA-170834 Signaling by TGF-beta Receptor Complex 20/1156 0.003584897 
R-HSA-190236 Signaling by FGFR 19/1156 0.029938298 
R-HSA-6794362 Protein-protein interactions at synapses 19/1156 0.029938298 
R-HSA-1483255 PI Metabolism 19/1156 0.022315083 
R-HSA-422356 Regulation of insulin secretion 19/1156 0.011951844 
R-HSA-2219530 Constitutive Signaling by Aberrant PI3K in Cancer 19/1156 0.008660319 
R-HSA-375165 NCAM signaling for neurite out-growth 19/1156 0.001954227 
R-HSA-8986944 Transcriptional Regulation by MECP2 18/1156 0.003584897 
R-HSA-2428928 IRS-related events triggered by IGF1R 18/1156 0.001242358 
R-HSA-2428924 IGF1R signaling cascade 18/1156 0.001242358 
R-HSA-2404192 
Signaling by Type 1 Insulin-like Growth Factor 1 Receptor 
(IGF1R) 18/1156 0.001242358 
R-HSA-74751 Insulin receptor signaling cascade 18/1156 0.001242358 
R-HSA-204998 Cell death signaling via NRAGE, NRIF and NADE 17/1156 0.034373093 
R-HSA-5654738 Signaling by FGFR2 17/1156 0.027147437 
R-HSA-373755 Semaphorin interactions 17/1156 0.010219801 
R-HSA-9614085 FOXO-mediated transcription 17/1156 0.010219801 
R-HSA-1226099 Signaling by FGFR in disease 17/1156 0.008125866 
R-HSA-109606 Intrinsic Pathway for Apoptosis 17/1156 0.001954227 
R-HSA-199992 trans-Golgi Network Vesicle Budding 16/1156 0.041188869 
R-HSA-193648 NRAGE signals death through JNK 16/1156 0.010219801 
R-HSA-3000171 Non-integrin membrane-ECM interactions 15/1156 0.021341993 
R-HSA-6794361 Neurexins and neuroligins 15/1156 0.014426919 
R-HSA-112399 IRS-mediated signaling 15/1156 0.004461806 
R-HSA-1433557 Signaling by SCF-KIT 15/1156 0.001954227 
R-HSA-8853659 RET signaling 15/1156 0.001715811 
R-HSA-2173793 
Transcriptional activity of SMAD2/SMAD3:SMAD4 
heterotrimer 14/1156 0.005510192 
R-HSA-1660499 Synthesis of PIPs at the plasma membrane 13/1156 0.040735265 
R-HSA-5654736 Signaling by FGFR1 13/1156 0.029837407 
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R-HSA-109704 PI3K Cascade 13/1156 0.012211791 
R-HSA-5655253 Signaling by FGFR2 in disease 13/1156 0.010385519 
R-HSA-419037 NCAM1 interactions 13/1156 0.009268756 
R-HSA-5655302 Signaling by FGFR1 in disease 13/1156 0.004461806 
R-HSA-2559585 Oncogene Induced Senescence 12/1156 0.004461806 
R-HSA-9022692 Regulation of MECP2 expression and activity 12/1156 0.004461806 
R-HSA-114452 Activation of BH3-only proteins 12/1156 0.002253121 
R-HSA-5654743 Signaling by FGFR4 11/1156 0.040476774 
R-HSA-5654741 Signaling by FGFR3 11/1156 0.034487419 
R-HSA-5654696 Downstream signaling of activated FGFR2 11/1156 0.006055974 
R-HSA-187687 Signaling to ERKs 10/1156 0.032398328 
R-HSA-5654687 Downstream signaling of activated FGFR1 10/1156 0.019938575 
R-HSA-4090294 SUMOylation of intracellular receptors 10/1156 0.015713737 
R-HSA-442742 
CREB1 phosphorylation through NMDA receptor-mediated 
activation of RAS signaling 10/1156 0.015713737 
R-HSA-452723 Transcriptional regulation of pluripotent stem cells 10/1156 0.004461806 
R-HSA-5654716 Downstream signaling of activated FGFR4 9/1156 0.024622519 
R-HSA-5654708 Downstream signaling of activated FGFR3 9/1156 0.015713737 
R-HSA-9634638 
Estrogen-dependent nuclear events downstream of ESR-
membrane signaling 9/1156 0.012426358 
R-HSA-2173795 
Downregulation of SMAD2/3: SMAD4 transcriptional 
activity 9/1156 0.010219801 
R-HSA-5654695 PI-3K cascade: FGFR2 9/1156 0.010219801 
R-HSA-5655332 Signaling by FGFR3 in disease 9/1156 0.008025745 
R-HSA-8853338 Signaling by FGFR3 point mutants in cancer 9/1156 0.008025745 
R-HSA-8934593 Regulation of RUNX1 Expression and Activity 9/1156 0.001954227 
R-HSA-400685 Sema4D in semaphorin signaling 8/1156 0.040735265 
R-HSA-5654700 FRS-mediated FGFR2 signaling 8/1156 0.040735265 
R-HSA-9006115 Signaling by NTRK2 (TRKB) 8/1156 0.040735265 
R-HSA-3232118 SUMOylation of transcription factors 8/1156 0.01467157 
R-HSA-1433559 Regulation of KIT signaling 8/1156 0.004461806 
R-HSA-1181150 Signaling by NODAL 7/1156 0.040735265 
R-HSA-2028269 Signaling by Hippo 7/1156 0.040735265 
R-HSA-5654720 PI-3K cascade: FGFR4 7/1156 0.040735265 
R-HSA-416700 Other semaphorin interactions 7/1156 0.034373093 
R-HSA-5654710 PI-3K cascade: FGFR3 7/1156 0.027922803 
R-HSA-881907 Gastrin-CREB signaling pathway via PKC and MAPK 7/1156 0.027922803 
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R-HSA-9022699 MECP2 regulates neuronal receptors and channels 7/1156 0.021496752 
R-HSA-392517 Rap1 signaling 7/1156 0.015713737 
R-HSA-5637810 Constitutive Signaling by EGFRvIII 6/1156 0.040476774 
R-HSA-5637812 Signaling by EGFRvIII in Cancer 6/1156 0.040476774 
R-HSA-169893 Prolonged ERK activation events 6/1156 0.030718533 
R-HSA-418359 Reduction of cytosolic Ca++ levels 6/1156 0.030718533 
R-HSA-170968 Frs2-mediated activation 6/1156 0.015713737 
R-HSA-5655291 Signaling by FGFR4 in disease 6/1156 0.010682553 
R-HSA-8853334 Signaling by FGFR3 fusions in cancer 6/1156 0.007452663 
R-HSA-8875555 MET activates RAP1 and RAC1 5/1156 0.041204888 





Appendix F / IPA(Qiagen) 
Qiagen integrity pathway analysis (IPA) was a user-friendly software to interpret 
bioinformatic data. 159 microRNA of different expression in neutrophils and NDMV was 
used to predict their probable network shown in Figure F. 
 
 
Figure F1. List of molecules in network and their score evaluated by IPA. 
 
 





Figure F3. Interaction of target genes and NDMV microRNA in Network 1. As NDMV 
microRNA were exogenous small RNA, up-stream molecules of microRNA were 





Appendix G / Pre-treatment of NDMV and Treatment of TNFα to FLS 
 
 
Figure G. The schedule of NDMV to pre-treat FLS on 6, 24h after FLS adhere to 6-well 
plates. 
